CN1359373A - 6[(aryl and heteroaryl)oxy] methyl] naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof - Google Patents
6[(aryl and heteroaryl)oxy] methyl] naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof Download PDFInfo
- Publication number
- CN1359373A CN1359373A CN00809874A CN00809874A CN1359373A CN 1359373 A CN1359373 A CN 1359373A CN 00809874 A CN00809874 A CN 00809874A CN 00809874 A CN00809874 A CN 00809874A CN 1359373 A CN1359373 A CN 1359373A
- Authority
- CN
- China
- Prior art keywords
- group
- formula
- compound
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims description 12
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 125000003118 aryl group Chemical group 0.000 title description 5
- 125000001072 heteroaryl group Chemical group 0.000 title description 3
- URXJHZXEUUFNKM-UHFFFAOYSA-N naphthalene-2-carboximidamide Chemical class C1=CC=CC2=CC(C(=N)N)=CC=C21 URXJHZXEUUFNKM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 125000003277 amino group Chemical group 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
- -1 benzo-1, 3-dioxolan-6-ylmethyl Chemical group 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 73
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 229910005960 SO2 a Inorganic materials 0.000 claims description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 4
- 150000002825 nitriles Chemical group 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000007822 coupling agent Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 152
- 239000000243 solution Substances 0.000 description 118
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 78
- 239000000047 product Substances 0.000 description 74
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 239000012074 organic phase Substances 0.000 description 41
- 239000012429 reaction media Substances 0.000 description 41
- 229920006395 saturated elastomer Polymers 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 239000007787 solid Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 230000008018 melting Effects 0.000 description 32
- 238000002844 melting Methods 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- 235000011152 sodium sulphate Nutrition 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 238000010992 reflux Methods 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 239000012043 crude product Substances 0.000 description 16
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 108010054265 Factor VIIa Proteins 0.000 description 9
- 108010000499 Thromboplastin Proteins 0.000 description 9
- 102000002262 Thromboplastin Human genes 0.000 description 9
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 9
- 229940012414 factor viia Drugs 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000007868 Raney catalyst Substances 0.000 description 7
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 7
- 229910000564 Raney nickel Inorganic materials 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 6
- ORUYTMCMDRSBEU-UHFFFAOYSA-N 6-(bromomethyl)naphthalene-2-carbonitrile Chemical compound C1=C(C#N)C=CC2=CC(CBr)=CC=C21 ORUYTMCMDRSBEU-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 3
- KYVQUZIXEXJJED-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1CCC(C=O)C2=CC(OC)=CC=C21 KYVQUZIXEXJJED-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- MAARRMBCEFVKNV-UHFFFAOYSA-N (6-bromonaphthalen-2-yl)methanol Chemical compound C1=C(Br)C=CC2=CC(CO)=CC=C21 MAARRMBCEFVKNV-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- KNCXTOYNERTOJO-UHFFFAOYSA-N 2-bromo-6-(bromomethyl)naphthalene Chemical compound C1=C(Br)C=CC2=CC(CBr)=CC=C21 KNCXTOYNERTOJO-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- DQCTUNOBJMHLHP-UHFFFAOYSA-N 4-methoxybicyclo[4.2.0]octa-1(6),2,4-triene-7-carbonitrile Chemical compound COC1=CC=C2CC(C#N)C2=C1 DQCTUNOBJMHLHP-UHFFFAOYSA-N 0.000 description 2
- PCURJZMHSLMVLL-UHFFFAOYSA-N 6-(hydroxymethyl)naphthalene-2-carbonitrile Chemical compound C1=C(C#N)C=CC2=CC(CO)=CC=C21 PCURJZMHSLMVLL-UHFFFAOYSA-N 0.000 description 2
- XVZQKVKVDOXQJG-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1CCC(N)C2=CC(OC)=CC=C21 XVZQKVKVDOXQJG-UHFFFAOYSA-N 0.000 description 2
- WJNRAOKRAWFGFS-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid Chemical compound C1CCC(C(O)=O)C2=CC(OC)=CC=C21 WJNRAOKRAWFGFS-UHFFFAOYSA-N 0.000 description 2
- WNSFCXGFQVZDFL-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC1CC2=C1C=C(C=C2)O Chemical compound CC(C)(C)OC(=O)NCC1CC2=C1C=C(C=C2)O WNSFCXGFQVZDFL-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- HDOLOFMAZIQVBW-UHFFFAOYSA-N N-[[4-[(6-cyanonaphthalen-2-yl)methoxy]-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]methyl]-1-phenylmethanesulfonamide Chemical compound C1C2=CC=C(OCC=3C=C4C=CC(=CC4=CC=3)C#N)C=C2C1CNS(=O)(=O)CC1=CC=CC=C1 HDOLOFMAZIQVBW-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- QLKNTHXMJDKIQM-UHFFFAOYSA-N [2-(methoxymethyl)phenyl]-diphenylphosphane Chemical compound COCC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QLKNTHXMJDKIQM-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000003024 amidolytic effect Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 150000002084 enol ethers Chemical class 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- JEUBRLPXJZOGPX-UHFFFAOYSA-N methyl 6-bromonaphthalene-2-carboxylate Chemical compound C1=C(Br)C=CC2=CC(C(=O)OC)=CC=C21 JEUBRLPXJZOGPX-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- IICYBOWTBTXPKI-UHFFFAOYSA-N n-[7-[[6-(n'-hydroxycarbamimidoyl)naphthalen-2-yl]methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC2C3=CC(OCC=4C=C5C=CC(=CC5=CC=4)C(N)=NO)=CC=C3CCC2)=C1 IICYBOWTBTXPKI-UHFFFAOYSA-N 0.000 description 2
- CCLHNLRKXBKXLI-UHFFFAOYSA-N n-[[7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]-1-(1,3-thiazol-4-yl)methanesulfonamide Chemical compound C1CCC2=CC=C(OCC=3C=C4C=CC(=CC4=CC=3)C#N)C=C2C1CNS(=O)(=O)CC1=CSC=N1 CCLHNLRKXBKXLI-UHFFFAOYSA-N 0.000 description 2
- AZKDTTQQTKDXLH-UHFFFAOYSA-N naphthalene-2-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CC=C21 AZKDTTQQTKDXLH-UHFFFAOYSA-N 0.000 description 2
- IGXALCCFUFBKQT-UHFFFAOYSA-N naphthalene-2-carboximidamide hydrochloride Chemical compound Cl.C1=CC=CC2=CC(C(=N)N)=CC=C21 IGXALCCFUFBKQT-UHFFFAOYSA-N 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- WNDGYNNXHYCXTQ-UHFFFAOYSA-N tert-butyl N-[(7-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]carbamate Chemical compound OC1=CC=C2CCCC(C2=C1)CNC(OC(C)(C)C)=O WNDGYNNXHYCXTQ-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- PCZOZSATUTWXIC-UHFFFAOYSA-N tetraethylazanium;cyanide Chemical compound N#[C-].CC[N+](CC)(CC)CC PCZOZSATUTWXIC-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 1
- ZCCXAUXDUBMMGZ-UHFFFAOYSA-N (4-methoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl)methanamine Chemical compound COC1=CC=C2CC(CN)C2=C1 ZCCXAUXDUBMMGZ-UHFFFAOYSA-N 0.000 description 1
- IZFTUOURRWZHTA-UHFFFAOYSA-N (7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methanamine Chemical compound C1CCC(CN)C2=CC(OC)=CC=C21 IZFTUOURRWZHTA-UHFFFAOYSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- NZBZZSVXIBHSKR-UHFFFAOYSA-N 2-(6-bromonaphthalen-2-yl)acetonitrile Chemical compound C1=C(CC#N)C=CC2=CC(Br)=CC=C21 NZBZZSVXIBHSKR-UHFFFAOYSA-N 0.000 description 1
- NUVPJXUYFGWDGB-UHFFFAOYSA-N 2-[4-[[2-fluoro-3-[[4-[6-(N'-propan-2-ylcarbamimidoyl)-1H-benzimidazol-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]-N'-propan-2-yl-3H-benzimidazole-5-carboximidamide Chemical class CC(C)NC(=N)C1=CC2=C(C=C1)N=C(N2)C1=CC=C(OCC2=CC=CC(COC3=CC=C(C=C3)C3=NC4=C(N3)C=C(C=C4)C(=N)NC(C)C)=C2F)C=C1 NUVPJXUYFGWDGB-UHFFFAOYSA-N 0.000 description 1
- ORAXBZFDDWPRRD-UHFFFAOYSA-N 3-(4-methoxyphenyl)propanenitrile Chemical compound COC1=CC=C(CCC#N)C=C1 ORAXBZFDDWPRRD-UHFFFAOYSA-N 0.000 description 1
- LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 1
- DPZYSPOUFXBBKV-UHFFFAOYSA-N 3-[[7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]methylsulfamoylmethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CS(=O)(=O)NCC2C3=CC(OCC=4C=C5C=CC(=CC5=CC=4)C#N)=CC=C3CCC2)=C1 DPZYSPOUFXBBKV-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NVTBASMQHFMANH-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazole;hydron;chloride Chemical compound Cl.ClCC1=CSC=N1 NVTBASMQHFMANH-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- UDMSLMQMTQXFGC-UHFFFAOYSA-N 6-methoxy-4-(methoxymethylidene)-2,3-dihydro-1h-naphthalene Chemical compound C1=C(OC)C=C2C(=COC)CCCC2=C1 UDMSLMQMTQXFGC-UHFFFAOYSA-N 0.000 description 1
- IUOHSGKPQZJKIK-UHFFFAOYSA-N 7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid Chemical compound C1=C(C#N)C=CC2=CC(COC3=CC=C4CCCC(C4=C3)C(=O)O)=CC=C21 IUOHSGKPQZJKIK-UHFFFAOYSA-N 0.000 description 1
- JGGLDHOWTLTIOE-UHFFFAOYSA-N 7-hydroxy-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)CCCC2=C1 JGGLDHOWTLTIOE-UHFFFAOYSA-N 0.000 description 1
- GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- ICVZVZCTMCDPJV-UHFFFAOYSA-N Br.NCC1CCCC=2C=CC(=CC12)O Chemical compound Br.NCC1CCCC=2C=CC(=CC12)O ICVZVZCTMCDPJV-UHFFFAOYSA-N 0.000 description 1
- DANVESXQRXQPMO-UHFFFAOYSA-N C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)C(=O)OC Chemical compound C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)C(=O)OC DANVESXQRXQPMO-UHFFFAOYSA-N 0.000 description 1
- YKWFNLCEZRBPDC-UHFFFAOYSA-N C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)CNS(=O)(=O)CC=1C=C(C(=O)OC)C=CC1 Chemical compound C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)CNS(=O)(=O)CC=1C=C(C(=O)OC)C=CC1 YKWFNLCEZRBPDC-UHFFFAOYSA-N 0.000 description 1
- YPPWHIVBKGTHKM-UHFFFAOYSA-N C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)NC(OC(C)(C)C)=O Chemical compound C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)NC(OC(C)(C)C)=O YPPWHIVBKGTHKM-UHFFFAOYSA-N 0.000 description 1
- LCOKYBNMHVGGCY-UHFFFAOYSA-N C1C(C2=C1C=CC(=C2)OCC3=CC4=C(C=C3)C=C(C=C4)C#N)CN.Cl Chemical compound C1C(C2=C1C=CC(=C2)OCC3=CC4=C(C=C3)C=C(C=C4)C#N)CN.Cl LCOKYBNMHVGGCY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- SCGZWIFZXNFVBI-UHFFFAOYSA-N Cl.C(C)OC(C(C1=CC2=CC=C(C=C2C=C1)C#N)OC1=CC=2C(CCCC2C=C1)CN)=O Chemical compound Cl.C(C)OC(C(C1=CC2=CC=C(C=C2C=C1)C#N)OC1=CC=2C(CCCC2C=C1)CN)=O SCGZWIFZXNFVBI-UHFFFAOYSA-N 0.000 description 1
- SYYJFBFOQYJUTQ-UHFFFAOYSA-N Cl.NC1CCCC=2C=CC(=CC12)OCC=1C=C2C=CC(=CC2=CC1)C#N Chemical compound Cl.NC1CCCC=2C=CC(=CC12)OCC=1C=C2C=CC(=CC2=CC1)C#N SYYJFBFOQYJUTQ-UHFFFAOYSA-N 0.000 description 1
- UKVLBXVVEFODFE-UHFFFAOYSA-N Cl.NCC1CCCC=2C=CC(=CC12)OCC=1C=C2C=CC(=CC2=CC1)C#N Chemical compound Cl.NCC1CCCC=2C=CC(=CC12)OCC=1C=C2C=CC(=CC2=CC1)C#N UKVLBXVVEFODFE-UHFFFAOYSA-N 0.000 description 1
- OFRSRPULIJHSRN-UHFFFAOYSA-N Cl.NN=CC=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)NC(CC1=CC(=CC=C1)OC)=O Chemical compound Cl.NN=CC=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)NC(CC1=CC(=CC=C1)OC)=O OFRSRPULIJHSRN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- REJRLHZCDJKPGC-UHFFFAOYSA-N N-benzyl-7-[(6-methanehydrazonoylnaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalene-1-carboxamide hydrochloride Chemical compound Cl.NN=CC=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)C(=O)NCC1=CC=CC=C1 REJRLHZCDJKPGC-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UBSRCFOSCWRDCQ-UHFFFAOYSA-N O-(1,3-thiazol-4-ylmethyl) ethanethioate Chemical compound C(C)(OCC=1N=CSC1)=S UBSRCFOSCWRDCQ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 229910005948 SO2Cl Inorganic materials 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- XWZQYQZQBWAEPH-UHFFFAOYSA-N ethyl 2-(6-bromonaphthalen-2-yl)acetate Chemical compound BrC=1C=C2C=CC(=CC2=CC1)CC(=O)OCC XWZQYQZQBWAEPH-UHFFFAOYSA-N 0.000 description 1
- OXSVSTHLAUZCLA-UHFFFAOYSA-N ethyl 2-(6-cyanonaphthalen-2-yl)acetate Chemical compound C(#N)C=1C=C2C=CC(=CC2=CC1)CC(=O)OCC OXSVSTHLAUZCLA-UHFFFAOYSA-N 0.000 description 1
- NTUDJMHFIZFGFN-UHFFFAOYSA-N ethyl 2-bromo-2-(6-cyanonaphthalen-2-yl)acetate Chemical compound CCOC(=O)C(C1=CC2=C(C=C1)C=C(C=C2)C#N)Br NTUDJMHFIZFGFN-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical class OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical class C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- HMRCZKQIOFZACX-UHFFFAOYSA-N lithium;trimethylsilylazanide Chemical compound [Li+].C[Si](C)(C)[NH-] HMRCZKQIOFZACX-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- MPSZOFVFBSGSCN-UHFFFAOYSA-N methyl 2-dimethylphosphorylacetate Chemical compound COC(=O)CP(C)(C)=O MPSZOFVFBSGSCN-UHFFFAOYSA-N 0.000 description 1
- QFJXEOZOBANBNV-UHFFFAOYSA-N methyl 3-(chlorosulfonylmethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CS(Cl)(=O)=O)=C1 QFJXEOZOBANBNV-UHFFFAOYSA-N 0.000 description 1
- YACGNGQPYPCGOL-UHFFFAOYSA-N methyl 6-cyanonaphthalene-2-carboxylate Chemical compound C1=C(C#N)C=CC2=CC(C(=O)OC)=CC=C21 YACGNGQPYPCGOL-UHFFFAOYSA-N 0.000 description 1
- MZDGXTXYHXDWIM-UHFFFAOYSA-N methyl benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1 MZDGXTXYHXDWIM-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- QHAMBPGPSSQLAG-UHFFFAOYSA-N n-[7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC2C3=CC(OCC=4C=C5C=CC(=CC5=CC=4)C#N)=CC=C3CCC2)=C1 QHAMBPGPSSQLAG-UHFFFAOYSA-N 0.000 description 1
- QUBKSWKQWZALNP-UHFFFAOYSA-N n-benzyl-7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalene-1-carboxamide Chemical compound C1CCC2=CC=C(OCC=3C=C4C=CC(=CC4=CC=3)C#N)C=C2C1C(=O)NCC1=CC=CC=C1 QUBKSWKQWZALNP-UHFFFAOYSA-N 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZNQPIVMKKOIOKM-UHFFFAOYSA-N tert-butyl N-[[7-[(6-cyanonaphthalen-2-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]carbamate Chemical compound C(#N)C=1C=C2C=CC(=CC2=CC1)COC1=CC=C2CCCC(C2=C1)CNC(OC(C)(C)C)=O ZNQPIVMKKOIOKM-UHFFFAOYSA-N 0.000 description 1
- SNNCYMWCEBMKBG-UHFFFAOYSA-N tert-butyl n-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate Chemical compound C1CCC(NC(=O)OC(C)(C)C)C2=CC(OC)=CC=C21 SNNCYMWCEBMKBG-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
The invention concerns compounds of general formula (I) wherein: R1 represents either a hydrogen atom, or an amino group, or a C1-C4 alkyl group, or a C1-C6 alkoxycarbonyl group, or a -OH group; R2 represents either a C1-C6 alkyl group, or a phenyl or benzyl group, or a -CH2Q group, wherein Q is a heterocyclic group; R3 and R5 represent independently of each other for example either a hydrogen atom, or a C1-C4 alkyl group, or a -COOH group; R4 represents either a hydrogen atom, or a C1-C4 alkyl group, or a -(CH2)p-COOR8 group; Z represents either a -CH- group, or a nitrogen atom. The invention also concerns the methods of preparation and therapeutic use of said compounds.
Description
The object of the present invention are 6- [ [ (aryl or heteroaryl) oxy ] methyl ] -naphthyl-2-carboximidamide (carboximidamide) derivatives, their preparation and their use in therapy.
R1to represent
A hydrogen atom, and a nitrogen atom,
or an amino group, or a salt thereof,
or C1~C4An alkyl group, a carboxyl group,
or C1~C6An alkoxycarbonyl group, a carbonyl group,
or an-OH group, or a group,can be in the form of tautomersThe form (a) of (b) exists,
R2to represent
C1~C6An alkyl group which may be substituted with 1 to 3 fluorine atoms,
or a cyclohexyl-methyl group,
or 2, 3-dihydro-1, 4-benzodioxy (benzodiox) -7-ylmethyl,
or benzo-1, 3-dioxolan-6-ylmethyl,
or phenyl, benzyl or phenethyl, wherein the phenyl groups can be respectively and independently selected from 1 to 3-N (CH)3)2Trifluoromethoxy group, methylthio group, C1~C4Alkoxy, trifluoromethyl, amino, nitro, C1~C4Alkyl, halogen atom, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Is substituted by radicals, where R8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or a group-CH2Q, where Q is a heterocyclic group, which may be selected from the group consisting of-N (CH)3)2Trifluoromethoxy group, C1~C4Alkoxy, trifluoromethyl, amino, nitro, C1~C4Alkyl, halogen atom, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Is substituted by radicals, where R8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
R3and R5Independently of each other represent
A hydrogen atom or a fluorine atom, or a salt thereof,
or C1~C4An alkyl group, a carboxyl group,
or-COOH, or a group of-COOH,
or a hydroxyl group, or a mixture of hydroxyl groups,
or-N (CH)3)2,
or-Y-CH2CO2H, wherein Y represents an oxygen atom or a nitrogen atom,
R4to represent
A hydrogen atom, and a nitrogen atom,
or C1~C4An alkyl group, a carboxyl group,
or- (CH)2)p-COOR8Where p is equal to 0, 1 or 2, R8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
x represents
-(CH2)mA group, where m is equal to 0, 1 or 2,
or-CR6R7-CH2-or-CH2-CR6R7A group, where R6And R7Each independently represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-NH-CO-or-CO-NH-groups,
or-NH-CH2-、-CH2-NH-、N(CH2)-CH2-、-CH2-N(CH3)-、-N(CH2CH3)-CH2-or-CH2-N(CH2CH3) The radical(s) is (are),
-a CH-group, in which,
or a nitrogen atom, or a mixture of nitrogen atoms,
and-A-B-C-represents
-a NH-CO-NH-group,
or an-NH-C (NH) -NH-group,
or- (CH)2)n-CO-NH groups, where n is equal to 0 or 1,
or- (CH)2)q-NR8-SO2-a group, where q is equal to 0, 1 or 2, and R8As before, represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or- (CH)2)q-NH-CO-group, where q is equal to 0 or 1,
or-CH2-NH-CO-NH-groups.
Within the scope of the present invention, the following terms have the following meanings:
alkyl is a linear or branched saturated hydrocarbon-containing chain,
the heterocyclic group is a hydrocarbon chain containing 5 to 6 link rings and containing one or two oxygen, sulfur and nitrogen heteroatoms, the rings can be aromatic or non-aromatic, and are selected from pyridine, pyrimidine, thiazole, imidazole, pyrrole, oxazole, thiophene, furan, pyrazine and other groups or isomers of the groups.
In the context of the present invention, halogen atoms are preferably chlorine and fluorine.
The compounds of the present invention may include one or several asymmetric carbons. They may thus be in the form of enantiomers or diastereomers. These enantiomers, diastereomers and mixtures thereof, including racemic mixtures, form part of the present invention.
The compounds of the invention may be in the form of the free base or an addition salt with a pharmaceutically acceptable acid, which also forms part of the invention.
Preferred compounds within the scope of the present invention are those in which,
R1to represent
A hydrogen atom, and a nitrogen atom,
or C1~C6An alkoxycarbonyl group, a carbonyl group,
or an-OH group, or a group,
R2to represent
C which may be substituted by trifluoromethyl1~C6An alkyl group, a carboxyl group,
or a cyclohexyl-methyl group,
or 2, 3-dihydro-1, 4-benzodioxo-7-ylmethyl,
or benzo-1, 3-dioxolan-6-ylmethyl,
or phenyl, benzyl or phenethyl, wherein the phenyl groups can be 1-3 independently selected from-N (CH)3)2Trifluoromethoxy group, methylthio group, C1~C4Alkoxy, trifluoromethyl, hydrogen radical, nitro radical, C1~C4Alkyl, halogen atom, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Is substituted by radicals, where R8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-CH2The group Q, where Q is a heterocyclic group, which may be selected from C1~C4Alkoxy, amino or-COOR8Is substituted by radicals, where R8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
R3and R5Independently of each other represent
A hydrogen atom, and a nitrogen atom,
or a-COOH group, or a group of-COOH,
or-CH3The radical(s) is (are),
R4to represent
A hydrogen atom, and a nitrogen atom,
or a-COOH group, or a group of-COOH,
x represents
-(CH2)mA group, where m is equal to 0 or 2,
or-CR6R7-CH2A group, where R6And R7Each independently represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-NH-CO-or-NH-CH2-a group of,
or-NH-CH2-or-CH2-N(CH2CH3) The radical(s) is (are),
z represents
-a CH-group, in which,
and-A-B-C-represents
-a NH-CO-NH-group,
or- (CH)2)n-CO-NH groups, where n is equal to 0 or 1,
or- (CH)2)q-NR8-SO2-a group, where q is equal to 0, 1 or 2, and R8Represents a hydrogen atom, and is represented by,
or- (CH)2)q-NH-CO-group, where q is equal to 0 or 1,
or-CH2-a NH-CO-NH-group,
or-CH2-CO-NH groups.
According to the invention, the compounds of general formula (I) can be synthesized according to scheme 1. FIG. 1 schematically shows
Reacting a compound of formula (II) with a compound of formula (III) in the presence of a base such as potassium carbonate in an aprotic solvent, preferably acetonitrile or dimethylformamide, at a temperature of 20 to 80 ℃ to give a compound of formula (IV); r in the formula (II)3And R4As defined above (if R is4Is a-COOH group, in fact in the form of an ester, until a compound of formula (VI) is obtained) and D represents a leaving group, such as a halogen or a sulfonate; r in the formula (III)5X, Z, A and B are all as defined above (in fact when B is ultimately the group-CO-, it is-CO-during the synthesis2-groups) and GP represent amine or carboxylic acid protecting groups, such as C1~C4Alkoxy or benzyloxy. In addition, the compound of the general formula (IV) can be prepared by Mitsunobu reaction of a compound of the general formula (II) in which D represents a hydroxyl group, with a compound of the general formula (III) condensed in the presence of diethyl azodicarboxylate or 1, 1' - (azodicarbonyl) dipiperidine and a trialkylphosphine or triarylphosphine, such as tri-n-butylphosphine or triphenylphosphine, in, for example, 1, 4-dioxane, tetrahydrofuran or toluene at a temperature of 0 to 60 ℃.
Deprotection of a compound of formula (IV) wherein A represents- (CH) to give a compound of general formula (V) under conditions known to those skilled in the art2)q-a group, where q may be 0, 1 or 2 and B represents a group-NR8-, where R is8Represents a hydrogen atom or C1~C4Alkyl Groups and GP represents amine protecting Groups such as tert-butyloxycarbonyl, trifluoroacetyl, trimethylsilylethoxycarbonyl or other various suitable protecting Groups as described in Protective Groups in Organic Synthesis, 2 nd edition, Wiley, NY, (1991) by T.Greene et al.
When referring to compounds of formula (IV) wherein A represents a group- (CH)2)n-, where n may be 0 or 1 and B represents a functional group-CO2-, where GP represents a carboxylic acid protecting group, such as methyl, ethyl, tert-butyl or others, as is known to those skilled in the artKnown and described in Protective groups in organic Synthesis, 2 nd edition, Wiley, NY, (1991), Greene et al convert these ester compounds of the general formula (IV) in which A is a Group- (CH) to free carboxylic acids of the general formula (V) by conventional methods, such as saponification with hydroxide ions, hydrolysis with inOrganic or organic acids, or reaction of silyl Protective groups, such as trimethylsilylethoxycarbonyl, with fluoride ions2) -, where n may be 0 or 1 and BH represents a functional group-CO2H。
Then, in the presence of organic base such as triethylamine, N-methylmorpholine or N, N-diisopropylethylamine in a solvent such as dichloromethane or dimethylformamide at the temperature of 0-60 ℃, the A in the formula is represented by- (CH)2)q-a group (where q may equal 0, 1 or 2), BH representing-NHR8And R is8A compound of the formula (V) as defined above, and wherein R2Formula R as defined above2-SO2Cl sulfonyl chloride to obtain a compound of a general formula (VI), wherein A represents- (CH)2)q-a group (where q may be equal to 0, 1 or 2), B represents-NR8A group and C represents-SO2-a group.
It is also possible to react A in the formula with a radical- (CH) under the conditions described above for the sulfonyl chloride2)q- (where q is equal to 0 or 1), BH representing an amino function
Or directly with R in the formula2Formula R as defined above2-N ═ C ═ O isocyanate reaction;
or with triphosgene or equivalent compound and then with R in the formula2Formula R as defined above2-NH2Reaction of the amine to give a compound of the general formula (VI) in which A represents the group-NH-or-CH2-NH-, B represents a group-CO-, and C represents a group-NH-.
In the formula, A represents a group- (CH)2)qAnd BH represents an amino function or a group-NHR8A compound of the general formula (V) of (1),
or in the presence of an organic base with R in the formula2Formula R as defined above2-reaction of COCl acid chlorides, their corresponding mixed anhydrides or active esters;
or with R in the formula in a solvent such as dichloromethane, dimethylformamide or a mixture of the two, in the presence of a coupling agent such as N' - (3-dimethylaminopropyl) -N-ethylcarbodiimide/1-hydroxybenzotriazole or [0- (7-azabenzotriazol-1-yl) -1, 1, 3, 3-tetramethyluronium (uronium) hexafluorophosphate or a peptide coupling agent known in the art, at a temperature of 0 to 25 ℃2Formula R as defined above2-CO2H carboxylic acid to obtain the compound of the general formula (VI), wherein A represents- (CH)2)q-, where q is equal to 0 or 1, B represents a group-NH-, and C represents a group-CO-.
To obtain a compound in which A represents a group- (CH)2)n- (where n is equal to 0 or 1), B represents a group-CO-and C represents a group-NH-a compound of formula (VI) in which A represents a group- (CH)2)n- (where n is equal to 0 or 1), BH representing a group-CO2H a compound of the general formula (V) and R in the formula2Formula R as defined above2-NH2The amine is reacted under peptide coupling conditions as specified above.
In order to obtain a compound of formula (VI) in which A-B-C-represents a group-NH-C (NH) -NH-, A represents a group- (CH)2)q- (where q is equal to 0 or 1), BH represents an amine function, and R in the formula2Formula R as defined above2And reacting N-C-S isothiocyanate. The thiourea thus obtained can be converted to guanidine by alkylation with methyl iodide and substitution with an ammonia source, such as ammonium acetate or ammonium carbonate.
The compounds of the general formula (I) can subsequently be obtained from these compounds of the general formula (VI), for example by arranging the nitrile groups as amidino groups by the two processes A and B described below.
The method A comprises the following steps: the compound of the general formula (VI) dissolved in saturated hydrogen sulfide of a triethylamine/pyridine mixture (1: 9) is treated for 20 to 36 hours at normal temperature. The thioamides thus formed are alkylated by refluxing an excess of methyl iodide in acetone, for example in the presence of ammonium acetate or of the formula R1-NH2The resulting intermediate is heated under reflux in an alcohol such as methanol in the presence of a nitrogen source of a primary amine to give the compound of formula (I).
The method B comprises the following steps: the compound of formula (VI) is treated with hydroxylamine hydrochloride in an alcohol, preferably ethanol, in the presence of an organic base such as triethylamine at a temperature of 40 to 70 ℃. Under the pressure of 20-50 psi and the temperature of 20-60 ℃, in the alcohol such as methanol or ethanol, in the presence of active Raney nickel and a few equivalents of hydrochloric acid or acetic acid, the obtained hydroxyamidine (R in the formula)1Compounds of the general formula (I) ═ OH) are hydrogenated to give compounds of the formula R1A compound represented by the general formula (I) wherein is a hydrogen atom.
If desired R in the formula1Is a group C1~C6The compound of the general formula (I) of alkoxycarbonyl is prepared by dissolving R in a solvent such as dichloromethane, tetrahydrofuran or acetonitrile in the presence of 1, 1, 3, 3-tetramethylguanidine, triethylamine or diisopropylethylamine at a temperature of 0-25 DEG C1A compound of formula (I) ═ H is reacted with an alkyl chloroformate.
The compounds of formula (II) can be synthesized by methods known to those skilled in the art. By way of example, several synthetic methods for the compounds of the general formula (II) are given in schemes 2 and 3.
FIG. 2 is a schematic view of
According to scheme 2, the bromo ester compound of formula (VII) is treated with a cyanide source such as copper cyanide in dimethylformamide at 50-140 deg.C, or in a solvent such as triethylamine or tributylamine at 80-160 deg.C in palladium (0)) The catalyst, such as tetrakis (triphenylphosphine) palladium (0), is treated with trimethylsilyl cyanide in the presence of palladium (0), or zinc cyanide in dimethylformamide in the presence of palladium (0), such as tetrakis (triphenylphosphine) palladium (0), at 80 ℃ to give the nitrile of formula (VIII). The ester function can be reduced by a number of methods known in the art, for example by reaction with lithium borohydride in an aprotic solvent such as tetrahydrofuran at a temperature of 0 to 80 ℃. Treating the thus obtained compound of formula (IX) with a reagent such as phosphorus tribromide or sulfuryl chloride in a solvent such as dichloromethane or chloroform at a temperature of 0 to 60 ℃ to obtain a compound of formula (II) wherein R4Represents a hydrogen atom, and D represents a halogen. The compounds of formula (IX) may also be converted into sulfonates, such as methanesulfonates, according to methods known to those skilled in the art.
If desired, to prepare R in the formula4Represents a group-COOR8(where R is8Represents a hydrogen atom or a group C1~C4Alkyl), and D represents a hydroxyl function or a halogen atom, can be operated, for example, according to scheme 3, where the compound of formula (II) is R4Represents the group-CO2CH2CH3The compound of (1).
According to scheme 3, the ester derivatives of formula (VII) are first reduced to alcohol derivatives of formula (X) with, for example, lithium aluminum hydride in tetrahydrofuran at a temperature of-20 ℃ to-10 ℃. The hydroxy function of the compound of formula (X) is converted to the halogen atom (Hal) chlorine or bromine by reactions common in the art, such as with phosphorus tribromide or sulphuryl chloride under the conditions previously described. At a temperature of 0-25 ℃ in dichloromethane, a compound of formula (XI) is obtained in which the halogen atom is replaced by a cyanide source, preferably tetraethylammonium cyanide. By the reaction of a compound of the formula R8Alcohols of-OH (R)8Is represented by C1~C4Alkyl), the nitrile function of the compound of formula (XII) thus obtained is converted into an ester by treatment with, for example, 95% sulfuric acid under reflux.
The compound of the formula (XIII) is obtained, which is preferably reacted with zinc cyanide in dimethylformamide in the presence of tetrakis (triphenylphosphine) palladium (O). To give the derivatives of the formula (XIV)
Or into compounds of the general formula (II) in which D represents a bromine atom and R represents a bromine atom, by the action of N-bromosuccinimide in the presence of catalytic amounts of 2, 2' -aza-bis (2-methylpropanenitrile) or benzoyl peroxide at reflux in carbon tetrachloride4Represents the group-CO2CH2CH3;
Or converted by oxidation into glyoxylic acid derivatives of the general formula (XV) by means of selenium dioxide refluxed in pyridine. Selective reduction of a compound of formula (XV), preferably with sodium borohydride in tetrahydrofuran at low temperature, provides a compound of formula (II) wherein D represents a hydroxyl function and R4Represents the group-CO2CH2CH3。
The compounds of formula (III) may be prepared according to scheme 4. FIG. 4 is a schematic view of
The ketones of the general formula (XVII) are commercially available and can be prepared according to the methods described in the literature or according to known modifications.
By way of example, substituted tetralones of the general formula (XVII) in which Z represents a group-CH-are described in U.S. Pat. No. 4, 3,980,699 and in European patent application 0540051. Compounds of the general formula (XVII) in which Z represents a nitrogen atom, in which Z represents a radical-CH-and X represents-NH-CH-, are prepared according to EP-3132952The compounds of the general formula (XVII) are prepared according to the modified method described in journal of the American chemical society (J.Amer.chem.Soc.)71, p.1901 (1949). The compounds of formula (XVIII) in which Z represents a group-CH-and X represents a group-NH-CO or-CONH-, are according to the chemistry described in FrancePrepared as described in the Association bulletin (Bull. Soc. Chim. Fr.)1, page 98 (1988). In which Z represents a group-CH2-and X represent a group-CH2-NH-or-CH2The compounds of the general formula (XVII) which are N-alkyl can be prepared according to a variant of the Pictet-Gram method described in chem.Ber. 42, p 2943 (1909) and in Org.React 6, p 151 (1951). Compounds of the general formula (XXII) in which Z represents a nitrogen atom and X represents a group-NH-CO-, can be prepared by a modification of the process described in "chem.soc." (J.Chem.Soc.) Perkin Trans 1, p.353 (1991). Compounds of formula (XXII) wherein Z represents a group-CH-and X represents a group-CO-NH-may be prepared according to the methods described in the report on Chemicals (chem.pharm.Bull.), 16(3), page 455 (1968).
In addition, indanones are commercially available.
According to scheme 4, R can be5The compounds of general formula (XVII) in which X and Z are as defined above, are subjected to the following reactions:
according to journal of the American society of chemistry 93, page 2897 (1971), the reductive amination is carried out directly with ammonium acetate and cyanoborohydride in methanol at ambient temperature:
or indirect reaction in two stages, under the usual conditions to give the oxime, which is then reduced with iron in acetic acid, or with lithium aluminium hydride, or by hydrogenation in the presence of palladium on carbon and acetic anhydride, to give the compound of the formula (XVIII). The compound of formula (XVIII) thus obtained is subsequently freed from methyl groups by reaction with 48% hydrobromic acid under reflux or, preferably, with boron tribromide in dichloromethane at low temperature (-70 to-20 ℃). The amine function of the resulting compound of the formula (XIX) may then be protected with an amine Protecting group, such as tert-butoxycarbonyl, trimethylsilylethoxycarbonyl, trifluoroacetyl, or other Protecting Groups as described in Greene, organic Synthesis, Wiley, NY, 1991. Thus obtaining a compound of the general formula (III) wherein A represents- (CH)2)q-, where q is equal to 0, and B represents a group-NH-, GP represents a protecting group.
To obtain a compound in which A represents a group- (CH)2)q-, where q is equal to 1 and B represents a group-NH-, the starting ketone of the formula (XVII) is first converted into an enol ether of the formula (XX) by a Wittig reaction with (methoxymethyl) triphenylphosphine in tetrahydrofuran at a temperature of less than 0 ℃. The enol ether of formula (XX) is then hydrolyzed to the aldehyde of formula (XXI) in a refluxing mixture of water-tetrahydrofuran or water-dioxane with the aid of an organic acid such as formic acid or p-toluenesulfonic acid. In this case, the compound of the formula (XXI) is converted into the amine of the formula (XXII) under the conditions described above for the preparation of the compound of the formula (XVIII). The methyl group of the compound of formula (XXII) is then removed, preferably at low temperature, with boron tribromide in a solvent such as dichloromethane, and the amine functionality of the resulting compound of formula (XXIII) is protected as described above for the compound of formula (XIX) to give the compound of formula (III), wherein A represents- (CH)2)q-, where q is equal to 1, B represents the group-NH-, and GP is an amine protecting group as described above.
The compounds of formula (XXII) may also be prepared by reacting a compound of formula (XVII) with trimethylsilylcyanide in dichloromethane in the presence of titanium tetrachloride (IV) and then hydrogenating the resulting nitrile intermediate in a solvent such as methanol at a pressure of 10 to 50psi in the presence of platinum oxide or palladium on carbon.
The aldehydes of formula (XXI) may also be oxidized to carboxylic acid derivatives of formula (XXIV) by reaction with a suitable oxidizing agent known to those skilled in the art, such as sodium hypochlorite. The compound of formula (XXIV) thus obtained is then demethylated with boron tribromide at low temperature and the carboxylic acid function of the compound of formula (XXV) is esterified in a usual manner, for example by heating in methanol saturated with hydrogen chloride gas. Thus obtaining a compound of the general formula (III) wherein A represents- (CH)2)n-, where n is equal to 0 and B represents a group-CO2And GP represents methyl.
To obtain a compound represented by the formula wherein A represents- (CH)2)n-, where n is equal to 1 and B represents a group-CO2The compounds of formula (III) in which-and GP represent methyl groups can be prepared according to scheme 5.
According to scheme 5, a compound of formula (XVII) can be reacted with the anion of methyl dimethylphosphorylacetate (obtained by deprotection with lithium trimethylsilylamide in tetrahydrofuran at a temperature of-50 to 20 ℃) to give an α, β -unsaturated ester of formula (XXVI). The compound of formula (XXVI) is then reduced to the compound of formula (XXVII) by catalytic hydrogenation, which is then demethylated with boron tribromide in dichloromethane at-70 ℃. To obtain a compound of the general formula (III) in which A represents- (CH)2)n-, where n is equal to 1 and B represents a group-CO2-, and GP represents methyl.
The following examples are intended to illustrate the invention without limiting its scope. The structure of the resulting compound was confirmed by microanalysis, nuclear magnetic resonance spectroscopy (RMN), mass spectrometry and infrared spectroscopy (IR). The numbering of the exemplified compounds is with reference to the tables given at the end, which illustrate the chemical structure and physical properties of certain compounds of the invention.
Example 1: (32# Compound)
6- [ [ [8- [ [ [ (thiazol-4-yl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidamide hydrochloride
1.1.6-cyanonaphthalene-2-carboxylic acid methyl ester
To a suspension of 7.50g (28.29mmol) of methyl 6-bromo-naphthalene-2-carboxylate degassed and 2.01g (17.0mmol) of zinc cyanide in 20mL of dimethylformamide was added 2.28g (1.97mmol) of tetrakis (triphenylphosphine) palladium (0), and the mixture was heated at 80 ℃ under nitrogen for 16 hours. The reaction medium is evaporated to dryness and the residue is dissolved in 300mL of ethyl acetate and filtered. The filtrate was washed twice with water and then with saturated aqueous sodium chloride solution. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The residue is purified by flash chromatography on silica gel (chromatofoash) eluting with an ethyl acetate/toluene mixture (1: 9).
5.20g of white crystals were obtained.
Melting point: 163 ℃ C.
Yield: 84 percent.
1.2.6- (hydroxymethyl) -naphthalene-2-carbonitrile
To a solution of 10.0g (47.35mmol) of methyl 6-cyanonaphthalene-2-carboxylate in 160mL of tetrahydrofuran cooled to 0 ℃ under nitrogen was added 2.06g (94.7mmol) of lithium borohydride in small portions and then returned to ambient temperature over 4.5 hours. The reaction mixture was then heated at reflux for 2 hours, cooled to 0 ℃ and hydrolyzed by the slow addition of 100mL of 1N hydrochloric acid. The tetrahydrofuran was distilled off under reduced pressure and the product was extracted with ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel eluting with an ethyl acetate/cyclohexane mixture (3: 7).
6.72g of product are obtained as a white solid.
Melting point: 129 ℃.
Yield: 78 percent.
1.3.6- (bromomethyl) -naphthalene-2-carbonitrile
To a solution of 20.0g (109.3mmol) of 6- (hydroxymethyl) naphthalene-2-carbonitrile dissolved in 600mL of dichloromethane cooled to 0 ℃ was added dropwise 4.1mL (43.7mmol) of phosphorus tribromide. The reaction medium is then stirred at 20 ℃ for 3 hours and then washed several times with saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness.
21.10g of an off-white solid are obtained.
Melting point: 138-139 ℃.
Yield: 78 percent.
1.4.7-methoxy-1- (methoxymethylene) -1, 2, 3, 4-tetrahydronaphthalene
To a solution of 60.0g (175mmol) of (methoxymethyl) -triphenylphosphine (chrysolite) in 500mL of anhydrous tetrahydrofuran cooled to-50 ℃ under nitrogen was added 19.65g (175mmol) of potassium tert-butoxide, and stirring was continued at-40 ℃ for 30 minutes. At this point a solution of 22.0g (125mmol) of 7-methoxy-1-tetralone (tetralone) in 250mL of anhydrous tetrahydrofuran was added dropwise. The reaction medium is then stirred at 20 ℃ for 3 hours and then hydrolyzed by the slow addition of 500mL of water. The organic phase was decanted and the aqueous phase was extracted with ethyl acetate. The organic phase was decanted and the aqueous solution was extracted with ethyl acetate aqueous solution. The organic phases are combined and washed with water, dried over sodium sulfate, filtered and evaporated to dryness. The resulting residue was triturated several times in cyclohexane and filtered to remove the precipitate. The filtrate was evaporated to dryness and the crude product was purified by flash chromatography on silica gel eluting with an ethyl acetate/cyclohexane mixture (5: 95).
25.94g of slurry were obtained and used as such in the next step.
1.5.7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carbaldehyde
A solution of 25.50g (125mmol) of 7-methoxy-1- (methoxymethylene) -1, 2, 3, 4-tetrahydronaphthalene and 7.50g (39.43mmol) of p-toluenesulfonic acid monohydrate in 200mL of 1, 4-dioxane and 50mL of water was refluxed for 2 hours. The reaction medium is then evaporated under reduced pressure and the residue is dissolved in 250mL of ethyl acetate. The solution was washed twice with water, the organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
24.1g of a pale yellow oil are obtained, which is used in the next step without further purification.
1.6.7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carbaldehyde oxime
To a solution of 11.10g (160mmol) of hydroxylamine hydrochloride and 25mL (180mmol) of triethylamine in 100mL of absolute ethanol at ambient temperature was added 28.70g (150 mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-al dissolved in 20mL of ethanol. The mixture was then heated at reflux for 2 hours and evaporated to dryness. The residue was dissolved in ethyl acetate, washed with 1M aqueous citric acid solution and then with saturated aqueous ammonium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness.
28.04g of product are obtained as a white solid.
Melting point: 147 ℃.
Yield: 93 percent.
1.7.7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-methanamine
To a solution of 10.0g (48.48mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carboxaldoxime in 200mL of anhydrous tetrahydrofuran at ambient temperature was added 49mL (49mmol) of a 1M solution of lithium aluminum hydride in tetrahydrofuran dropwise. The reaction medium is stirred at ambient temperature for 16 hours, and then hydrolysis is carried out by successively adding 1.9mL of water, 1.9mL of 1N sodium carbonate and then 5.6mL of water. Magnesium sulfate 50g was added, stirred for 5 minutes, and then filtered. The salt was washed with dichloromethane and the filtrate was evaporated to dryness. The residue was dissolved in ethyl acetate, the solution was washed successively with saturated aqueous ammonium chloride solution, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, and the organic phase was dried over magnesium sulfate, filtered and evaporated to dryness.
8.99g of the product are obtained as a colorless oil.
Yield: 88 percent.
1.8.8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-ol hydrobromide
To a solution of 9.50g (49.7mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-methanamine in 49mL of dichloromethane cooled to-78 deg.C was added 109mL (109mmol) of a 1M solution of boron tribromide in dichloromethane dropwise. The reaction medium is stirred at-78 ℃ for 30 minutes and then at ambient temperature for 30 minutes. 100mL of methanol was added dropwise at-78 ℃ for hydrolysis, followed by stirring at 20 ℃ for 1 hour. The medium was evaporated to dryness, then dissolved in toluene and evaporated again to dryness.
12.40g of an amorphous solid product having hygroscopicity was obtained.
Yield: 97 percent.
Melting point (hydrochloride salt): 181-183 ℃.
[ (7-hydroxy-1, 2, 3, 4-tetrahydronaphthalen-1-yl) -methyl ] -carbamic acid 1, 1-dimethylethyl ester
To a solution of 11.74g (45.50mmol) of 8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-ol hydrobromide in 360mL of tetrahydrofuran at 20 ℃ with stirring was added 11.70g (53.67mmol) of di-tert-butyl dicarbonate. Then 12.7mL (91mmol) of triethylamine were added dropwise and stirred at 20 ℃ for 4 hours. At this point, the reaction medium is evaporated to dryness and the residue is dissolved in 300mL of ethyl acetate. The solution was washed with water, the organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The crude product was then purified by flash chromatography on a silica gel eluting with an ethyl acetate/cyclohexane mixture (1: 9).
8.15g of a gum-like product are obtained.
Yield: 68 percent.
1.10.[ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -carbamic acid 1, 1-dimethylethyl ester
A solution of a mixture of 4.40g (17.8mmol)6- (bromomethyl) naphthalene-2-carbonitrile, 4.0g (14.4mmol) [ (7-hydroxy-1, 2, 3, 4-tetrahydronaphthalen-1-yl) -methyl ] -carbamic acid-1, 1-dimethylethyl ester and 3.20g (23.3mmol) potassium carbonate in 120mL acetonitrile was refluxed for 6 hours. The reaction medium is evaporated to dryness, the crude product is purified by flash chromatography on silica gel, eluting with a mixture of ethyl acetate/cyclohexane (1: 4).
5.60g of product are obtained as a white solid.
Melting point: 122 deg.C.
The yield thereof was found to be 87%.
1.11.6- [ [ [8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride
A solution of 4.70g (10.63mmol) [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -carbamic acid-1, 1-dimethylethyl ester in 100mL dichloromethane and 10mL 4N anhydrous hydrochloric acid in dioxane was stirred at 20 ℃ for 14 hours. The reaction medium is evaporated to dryness, the solid is triturated in ether, the liquid is removed and dried in vacuo.
3.80g of product are obtained as a white solid.
Melting point: 149-150 ℃.
Yield: 95 percent.
1.12. Thioacetic acid thiazol-4-yl methyl ester
A mixture of 3.50g (19.57mmol) of 4-chloromethylthiazole hydrochloride and 2.70g (19.57mmol) of potassium carbonate was stirred at 0 ℃ for 15 minutes. At this point 2.24g (19.57mmol) potassium thioacetate was added and stirring was continued at ambient temperature for 4 hours. The reaction medium is evaporated to dryness under reduced pressure and the residue is dissolved in diethyl ether. The solution was washed with ice water and then with saturated aqueous sodium chloride solution. The organic phase is dried over sodium sulfate, filtered and then evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with an ethyl acetate/cyclohexane mixture (3: 7) to give 2.35g of the expected product as an oil.
Yield: and 69 percent.
1.13. Thiazole-4-methanesulfonyl chloride hydrochloride
To a solution of 2.34g (13.53mmol) thiazol-4-ylmethyl thioacetate in 12mL acetic acid cooled to 0 deg.C was added 0.73mL (40.56mmol) of water, followed by 3.26mL (40.56mmol) of thionyl chloride dropwise, the temperature was allowed to rise to 20 deg.C, and then stirred at this temperature for 4 hours. The reaction medium is allowed to evaporate to dryness, the solid is triturated in ethyl acetate, then in ether and finally dried in vacuo.
1.95g of the expected product are obtained as a pale yellow solid.
Melting point: 170 deg.C.
Yield: 61 percent.
N- [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -thiazole-4-methanesulfonamide
Add 0.34g (1.45mmol) thiazole-4-methanesulfonyl chloride hydrochloride to a solution of 0.41g (1.20mmol)6- [ [ [3- (hydroxymethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carbonitrile in 20mL dichloromethane cooled to 0 deg.C, followed by 0.44mL (3.30mmol) triethylamine and stir at ambient temperature for 16 h. The reaction medium is then diluted in 100mL of dichloromethane and the solution is washed with saturated aqueous sodium chloride solution. The organic phase was dried over magnesium sulfate, filtered and evaporated. The crude product was then purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (2: 98) containing a small amount of concentrated ammonia.
0.304g of white foam/gum-like product was obtained.
Yield: 50 percent.
N' -hydroxy-6- [ [ [8- [ [ [ (thiazol-4-ylmethyl) -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalen-2-carboximidamide
A solution of 0.30g (0.60mmol) of N- [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -thiazole-4-methanesulfonamide, 0.103g (1.49mmol) of hydroxylamine hydrochloride and 0.20mL (1.49mmol) of a mixture of triethylamine in 30mL of anhydrous ethanol was refluxed at elevated temperature for 8 hours. The reaction medium is then evaporated to dryness, the solid is triturated in water, the water is removed and then dried in vacuo.
0.319g of product is obtained as a white solid.
Melting point: at 140 ℃.
Yield: 99 percent.
1.16.6- [ [ [8- [ [ [ (thiazol-4-ylmethyl) -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidamide hydrochloride
A mixture of 0.31g (0.576mmol) of N' -hydroxy-6- [ [ [8- [ [ [ (thiazol-4-ylmethyl) -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] naphthalene-2-carboximidic acid amide in a solution of 30mL of methanol, 3mL of acetic acid and 11.8mL of anhydrous hydrochloric acid in isopropanol was hydrogenated in the presence of 0.25g of active Raney nickel under a pressure of 40psi in a Parr apparatus for 12 hours. At this point the reaction medium is filtered and the filtrate evaporated to dryness. The crude product is purified by reverse phase flash chromatography using C18, eluting with methanol in 0.001N aqueous hydrochloric acid in a gradient of 10-50%.
0.164g of product was obtained as a white solid.
Melting point: 135 ℃ is adopted.
Example 2: (17# Compound)
N- [7- [ [6- (aminoiminomethyl) -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide hydrochloride
2.1.7-methoxy-1, 2, 3, 4-tetrahydronaphthalen-1-amine
To a solution of 17.60g (99.89mmol) of 7-methoxy-1-tetralone and 77.0g (1mol) of anhydrous ammonium acetate in 500mL of methanol at ambient temperature was added 5.10g (81.16mmol) of sodium cyanoborohydride, followed by stirring at this temperature for 96 hours. The methanol was distilled off under reduced pressure and replaced by 400mL of diethyl ether. The mixture was cooled to 0 ℃ and then hydrolyzed by adding 6N hydrochloric acid until the pH was 1. The aqueous phase is washed with 100mL of ether in 3 portions and then separated, the pH being adjusted to 9 with concentrated sodium hydroxide. At this point the product was extracted with ether, the organic phase was dried over sodium sulphate, filtered and evaporated to dryness.
16.13g of a colorless oily product were obtained.
Yield: 93 percent
2.2 (7-methoxy-1, 2, 3, 4-tetrahydronaphthalen-1-yl) carbamic acid 1, 1-dimethylethyl ester
16.0g (90.4mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalen-1-amine are added in small portions to 300mL of hydrobromic acid (48%), and the mixture is refluxed for 15 hours at elevated temperature. The reaction medium is evaporated to dryness and the residue is dissolved in 250mL of tetrahydrofuran. 21.80g (100.0mmol) of di-tert-butyl dicarbonate are added and then 30mL (215.24mmol) of triethylamine are added dropwise and stirred at ambient temperature for 17 hours. Adjusting the pH value of the reaction medium to 5-6 by using acetic acid, and then extracting by using ethyl acetate. Washed with water, and the organic phase is then dried over sodium sulfate, filtered and evaporated to dryness. After recrystallization from ethanol, 21.07g of a white solid was obtained.
Melting point: 72-73 DEG C
Yield: 88 percent.
2.3[7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -carbamic acid 1, 1-dimethylethyl ester
A mixture of 11.50g (46.8mmol)6- (bromomethyl) -naphthalene-2-carbonitrile, 10.0g (38.02mmol) 1, 1-dimethylethyl (7-methoxy-1, 2, 3, 4-tetrahydronaphthalen-1-yl) carbamate and 8.50g (61.51mmol) potassium carbonate in 300mL acetonitrile was refluxed at elevated temperature for 6 hours. The reaction mixture was then evaporated to dryness, eluting with ethyl acetate/cyclohexane (2: 8), and the crude product was purified by flash chromatography on silica gel.
14.13g of product are obtained as a white solid.
Melting point: 114-115 DEG C
Yield: 87 percent.
2.46- [ [ (8-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl) -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride
A solution of 1.0g (2.33mmol) of [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] carbamic acid 1, 1-dimethylethyl ester in 80mL of dichloromethane cooled to 5 ℃ is bubbled with a stream of hydrochloric acid for 5 minutes, then stirred at ambient temperature for 5 hours. The reaction medium is then evaporated to dryness, the solid is triturated in ether, the liquid is removed and then dried in vacuo.
0.850g of product is obtained.
Melting point: 222-223 DEG C
Yield: 100 percent.
2.5N- [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide
To a solution of 0.30g (1.81mmol) of 3-methoxyphenylacetic acid in 10mL of dichloromethane were added 0.66g (1.81mmol) of 6- [ [ 8-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride, 0.244g (1.81mmol) of 1-hydroxybenzotriazole, followed by 0.90mL (5.17mmol) of N, N-diisopropyl-N-ethylamine. The mixture was cooled to 0 ℃ and 0.38g (1.98mmol) of N' - (3-dimethylaminopropyl) -N-ethylcarbodiimide were added. The temperature was allowed to rise back to ambient temperature and stirred for 14 hours. The reaction medium is then diluted in 150mL of ethyl acetate and the solution is washed with 1N aqueous citric acid (3X 50mL), water (50mL), saturated aqueous sodium bicarbonate (3X 50mL) and finally saturated aqueous sodium chloride (50 mL). The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (5: 95).
0.802g of product is obtained.
Melting point: 146 deg.C
Yield: 92 percent of
N- [7- [ [6- [ amino (hydroxyimino) -methyl ] -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide
A mixture of 0.793g (1.66mmol) of N- [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide, 0.30g (4.31mmol) of hydroxylamine hydrochloride and 0.60mL (4.31mmol) of triethylamine in 50mL of anhydrous ethanol was heated under reflux for 6 hours. The reaction medium is then evaporated to dryness, the solid is triturated in 10mL of water, the water is removed and dried in vacuo. 0.768g of product is obtained as a white solid, yield: 90 percent.
2.7N- [7- [ [6- (aminoiminomethyl) naphthalen-2-yl ] methoxy ] -1, 2, 3, 4 tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide hydrochloride
0.760g (1.49mmol) of N- [7- [ [6- [ amino (hydroxyimino) -methyl ] -naphthalen-2-yl ] methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -3-methoxyphenylacetamide is stirred in 15ml of 0.1N isopropanol hydrochloride solution for 10 minutes and then evaporated to dryness. At this point the hydrochloride was dissolved in 30mL of methanol and 3mL of acetic acid and the solution was placed in a Parr apparatus and hydrogenated in the presence of 0.50g of active Raney nickel at 40 deg.C and 40psi for 5 hours. The reaction mixture was filtered over celite and the filtrate was evaporated to dryness. The crude product is purified by C-18 reverse phase HPLC using a gradient elution with 0-100% acetonitrile in 0.001N aqueous hydrochloric acid for 180 minutes.
0.150g of product is obtained.
Melting point: 120 deg.C
Yield: 20 percent of
Example 3: (Compound No. 5)
6- [ [ [8- [ [ (pyridin-3-ylmethyl) -amino ] -carbonyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] oxy ] -methyl ] naphthalen-2-carboximidamide hydrochloride
3.1.6- [ [ [8- [ [ (pyridin-3-ylmethyl) -amino ] -carbonyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] oxy ] methyl ] -naphthalene-2-carbonitrile
0.73g (2.00mmol) of 6- [ [ (8-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl) -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride in 20mL 1, 4-dioxane cooled to 5 ℃ was added 0.356g (1.20mmol) of bis (trichloromethyl) carbonate followed by 1.40mL (10mmol) of triethylamine. The mixture is stirred at ambient temperature for 30 minutes, and then 0.220g (2.03mmol) of 3-aminomethylpyridine are added to the isocyanate thus formed. The reaction mixture was stirred at 20 ℃ for 15 h, then 75mL of water was added and extracted with dichloromethane (3X 100 mL). The organic phase was collected, washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (5: 95).
0.707g of product was obtained.
Yield; 76 percent.
3.26- [ [ [8- [ [ (pyridin-3-ylmethyl) -amino ] -carbonyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] naphthalen-2-carboximidamide hydrochloride
A mixture of 0.265g (3.81mmol) hydroxylamine hydrochloride, 0.707g (1.53mmol)6- [ [ [8- [ [ (pyridin-3-ylmethyl) -amino ] -carbonyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] naphthalene-2-carbonitrile and 0.64mL (4.60mmol) triethylamine in 15mL anhydrous ethanol was heated at reflux for 5 hours. The reaction mixture was evaporated to dryness, the resulting solid was triturated in 10mL of water, water was removed and dried in vacuo. It was dissolved in 20mL of 0.1N isopropanol HCl solution and then evaporated to dryness. The hydrochloride salt was dissolved in 50mL of methanol/acetic acid (9: 1), and the solution was placed in a Parr apparatus and hydrogenated with 0.80g of active Raney nickel at 20 ℃ and 40psi for 13 hours. The reaction mixture was filtered and the filtrate was evaporated. Eluting with 20-100% gradient acetonitrile in 0.001N hydrochloric acid water solution, and purifying the product by reversed phase C18 flash chromatography.
0.315g of the product (dihydrochloride) is obtained as a white solid.
Melting point: 175 deg.C (decomposition).
Yield: 37 percent.
Example 4: (Compound No. 13)
6- [ [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidamide hydrochloride
4.1.3-Methoxybenzenesulfonyl chloride
A mixture of 10.0g (49.7mmol) of 3-methoxybenzyl bromide, 6.30g (50.0mmol) of sodium sulfite and 0.16g (0.50mmol) of tetra-n-butylammonium bromide in 35mL of water is heated at 95 ℃ for 2 hours. Then stirred at room temperature overnight and the reaction mixture was evaporated to dryness. 10.5g of the resulting 16.5g of solid was suspended in 135mL of methylene chloride, and 20.1g (96.5mmol) of phosphorus pentachloride was added in small portions at ordinary temperature. The reaction mixture was stirred at this temperature for 1 hour and then evaporated to dryness. The residue was dissolved in ethyl acetate, and the solution was washed with water and then with a saturated aqueous solution of sodium chloride. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
6.95g of oily product are obtained.
Yield: 98 percent.
N- [ [7- (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -3-methoxybenzenesulphonamide
To a mixture of 0.644g (1.17mmol)6- [ [ [8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride and 0.68mL (4.90mmol) triethylamine in 50mL dichloromethane was added a solution of 0.60g (2.72mmol) 3-methoxybenzenesulfonyl chloride in 10mL dichloromethane and stirred at 20 ℃ for 3 hours. The reaction mixture was then evaporated to dryness and the residue was dissolved in ethyl acetate. This solution was washed successively with 1M citric acid, saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with methanol/dichloromethane (2: 98).
0.382g of product is obtained in the form of a white foam.
Yield: 60 percent.
4.36- [ [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] naphthalen-2-carboximidamide hydrochloride
A mixture of 0.382g (0.73mmol) of N- [ [7- (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -3-methoxybenzenesulphonamide, 0.13g (1.87mmol) of hydroxylamine hydrochloride and 0.28mL (2.0mmol) of triethylamine was heated to reflux for 6 hours. The reaction mixture was evaporated to dryness, the solid was triturated in 10mL water, water was removed and dried in vacuo. The product was dissolved in 10mL of 0.1N isopropanol hydrochloride solution and the solution was evaporated to dryness. This hydrochloride salt was dissolved in 20mL of methanol/acetic acid (9: 1), charged to a Parr apparatus, and hydrogenated in the presence of 0.25g of active Raney nickel at 45psi pressure and 20 ℃ for 5 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. Eluting with 30-50% acetonitrile solution in 0.01N hydrochloric acid water solution, and purifying the product by reversed phase flash chromatography. 0.18g of product is obtained as a white solid.
Melting point: 250 deg.C (decomposition).
Yield: and 43 percent.
Example 5: (31# Compound)
7- [ [6- (aminoiminomethyl) -naphthalen-2-yl ] -methoxy ] -N- (phenylmethyl) -1, 2, 3, 4-tetrahydronaphthalene-1-carboxamide hydrochloride
5.1.7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid
To a two-phase solution of 3.88g (20.42mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carbaldehyde in 50mL of dichloromethane and 10mL of water cooled to 5 ℃ was added a solution of 2.0g (20.60mmol) of sulfamic acid in 20mL of water. A solution of 6.9g (61.03mmol) of 80% sodium hypochlorite in 20mL of water is then added dropwise over 1 hour, the reaction medium is stirred for 30 minutes at 20 ℃ and then diluted in 50mL of dichloromethane. The organic phase was separated and washed with saturated aqueous sodium sulfite solution. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
3.04g of amorphous solid product was obtained.
Yield: 72 percent.
5.2.7-hydroxy-1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid methyl ester
To a solution of 3.03g (14.71mmol) of 7-methoxy-1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid in 50mL of dichloromethane frozen to-70 ℃ was added dropwise 30mL (30mmol) of a 1M solution of boron tribromide in dichloromethane. The reaction medium is stirred at ambient temperature for 1 hour, then frozen to-78 ℃ and hydrolyzed with 5mL of methanol. The medium was evaporated to dryness and the residue was dissolved in 50mL of methanol. At this time, the solution was saturated with hydrogen chloride gas, and then heated under reflux for 2 hours. The medium is evaporated to dryness, the crude product is purified by flash chromatography on silica gel, eluting with a methanol/dichloromethane mixture (2: 98, then 5: 95).
2.10g of product are obtained.
Yield: 69 percent
5.3.7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid methyl ester
A mixture of 2.80g (11.38mmol)6- (bromomethyl) -naphthalene-2-carbonitrile, 1.90g (9.21mmol) and 2.06g (14.90mmol) potassium carbonate in 50mL acetonitrile was heated at reflux for 3.5 h. The reaction mixture was then cooled to ambient temperature, filtered and the filtrate evaporated to dryness. The residue obtained is purified by flash chromatography on silica gel, eluting with an ethyl acetate/toluene mixture (1: 9).
2.40g of the expected product are obtained as a colorless oil.
Yield: 70 percent.
5.4.7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid
To a solution of 2.39g (6.43mmol) of methyl 7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalene-1-carboxylate in 25mL of THF and 8mL of water cooled to 0 deg.C was added 3.88g (92.47mmol) of lithium hydroxide monohydrate, followed by stirring at ambient temperature for 24 hours. The tetrahydrofuran was evaporated under reduced pressure and the aqueous solution was washed with diethyl ether. The pH of the aqueous phase was then adjusted to 2 by addition of 1N hydrochloric acid. Extraction with ethyl acetate and drying of the organic phase over sodium sulfate, filtration and evaporation to dryness.
1.20g of the product was obtained as a colorless oil.
Yield: 52 percent.
5.5.7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -N- (phenylmethyl) -1, 2, 3, 4-tetrahydronaphthalene-1-carboxamide
To a solution of 0.50g (1.40mmol) of 7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid in 10mL of dioxane and 2mL of dimethylformamide at 5 ℃ were added 0.16mL (1.46mmol) of benzylamine, 0.21g (1.55mmol) of 1-hydroxybenzotriazole, 0.50mL (2.87mmol) of N, N-diisopropyl-N-ethylamine and then 0.30g (1.56mmol) of N' - (3-dimethylaminopropyl) -N-ethylcarbodiimide and stirred at ambient temperature for 14 h. The reaction mixture was then evaporated to dryness and the residue was dissolved in 200mL of dichloromethane. This solution was successively washed with a 1M aqueous citric acid solution, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (5: 95).
0.44g of product is obtained as a white solid.
Melting point: 181 ℃ is adopted.
The yield thereof was found to be 70%.
5.6.7- [ [6- (aminoiminomethyl) -naphthalen-2-yl ] -methoxy ] -N- (phenylmethyl) -1, 2, 3, 4-tetrahydronaphthalene-1-carboxamide hydrochloride
A solution of 0.44g (0.985mmol) of 7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -N- (phenylmethyl) -1, 2, 3, 4-tetrahydronaphthalene-1-carboxamide, 0.171g (2.45mmol) of hydroxylamine hydrochloride and 0.34mL (2.45mmol) of triethylamine in 15mL of ethanol was heated at reflux for 8 h. The reaction medium is then evaporated to dryness, the solid obtained is triturated in 10mL of water, the water is removed and dried in vacuo. The hydroxyamidine is dissolved in 10mL of isopropanol hydrochloride and the solution is evaporated to dryness. This hydrochloride is dissolved in a mixture of 20mL of methanol and 2mL of acetic acid and the solution is hydrogenated in the presence of 0.40g of active Raney nickel at 20 ℃ and a pressure of 45psi for 14 hours in a Parr apparatus. The product was purified by reverse phase HPLC using C18, eluting with a gradient of 0-100% acetonitrile in 0.001N hydrochloric acid for 180 minutes.
0.194g of product are obtained as a white solid.
Melting point: 225 ℃ is adopted.
Yield: 40 percent.
Example 6: (34# Compound)
6- (Aminoiminomethyl) -alpha- [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetic acid
6.1.6-bromonaphthalene-2-methanol
To a solution of 20.0g (75.44mmol) of methyl 6-bromonaphthalene-2-carboxylate in 325mL of tetrahydrofuran frozen to-20 ℃ was added 76mL (76.0mmol) of a 1M solution of lithium aluminum hydride in tetrahydrofuran dropwise. The medium was stirred for 30 minutes at-20 ℃ and then hydrolyzed by slowly adding 3mL of water, 3mL of 15% sodium carbonate, and then 10mL of water. The mixture was stirred at ambient temperature for 1 hour, then 75g magnesium sulfate was added and filtered. The filtrate was evaporated to dryness to give 17.24g of the product as a white solid.
Melting point: at 154 ℃.
Yield: 96 percent.
6.2.2-bromo-6- (bromomethyl) -naphthalene
A solution of 17.23g (72.67mmol) of 6-bromonaphthalene-2-methanol in 500mL of dichloromethane was brominated at 0 ℃ with the aid of 2.8mL (29.1mmol) of phosphorus tribromide. The medium is stirred at ambient temperature for 16 hours and then hydrolyzed by addition of 10mL of methanol. This solution was washed with water and then with a saturated aqueous solution of sodium chloride. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
19.7g of product are obtained as a white solid.
Melting point: 127 ℃.
The yield thereof was found to be 90%.
6.3.6-Bromomaphthalene-2-acetonitrile
To a solution of 16.70g (55.67mmol) 2-bromo-6- (bromomethyl) -naphthalene in 400mL dichloromethane cooled to 0 deg.C was added 9.60g (61.0mmol) tetraethylammonium cyanide, which was then stirred at ambient temperature for 3 hours. The solution was washed twice with water, the organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
13.62g of product are obtained as a pale yellow solid.
Melting point: 115 ℃ is carried out.
The yield thereof was found to be 99%.
6.4.6-Bromomaphthalene-2-acetic acid ethyl ester
80mL of concentrated sulfuric acid was added to a solution of 13.60g (55.26mmol) of 6-bromonaphthalene-2-acetonitrile in 140mL of ethanol at ambient temperature, followed by heating and refluxing for 2 hours. Most of the ethanol was distilled off under reduced pressure, and then the mixture was slowly poured onto 400g of crushed ice. Extraction with ethyl acetate was carried out, and the organic phase was then dried over sodium sulfate, filtered and evaporated to dryness.
15.70g of the expected product are obtained.
Yield: 97 percent.
6.5.6-Cyanonaphthalene-2-acetic acid ethyl ester
To a degassed suspension of 8.26g (28.19mmol) of ethyl 6-bromonaphthalene-2-acetate and 2.0g (17.03mmol) of zinc cyanide in 20mL of dimethylformamide was added 2.28g (1.97mmol) of tetrakis (triphenylphosphine) palladium (O), and the mixture was heated at 80 ℃ under nitrogen for 3 hours. The reaction mixture was evaporated to dryness and the residue was dissolved in 250mL of ethyl acetate and filtered. The filtrate was washed 3 times with 100mL of water and then with saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness. The residue was triturated in n-pentane and the resulting white precipitate was drained and dried in vacuo.
5.88g of product are obtained.
Melting point: and 65 ℃.
The yield thereof was found to be 87%
6.6. Alpha-bromo-6-cyanonaphthalene-2-acetic acid ethyl ester
To a mixture of 7.50g (31.35mmol) of ethyl 6-cyanonaphthalene-2-acetate and 8.37g (47.0mmol) of N-bromosuccinamide in 75mL of carbon tetrachloride was added 0.36g (2.19mmol) of 2, 2' -azobisisobutyronitrile, and the mixture was heated under reflux for 20 hours. The reaction medium is cooled to 5 ℃ and filtered. The filtrate was concentrated to 1/3, re-cooled to 5 ℃ and filtered again. The filtrate was evaporated to dryness, eluted with an ethyl acetate/cyclohexane mixture (1: 9) and the crude product was purified by flash chromatography on silica gel.
8.20g of oily product are obtained.
Yield: 82 percent.
6.7.6-cyano-alpha- [ [8- [ [ [ (1, 1-dimethylethoxy) -carbonyl ] -amino ] -methyl ] -5, 6, 7, 8- ] -tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetic acid ethyl ester
A mixture of 1.30g (4.09mmol) of ethyl α -bromo-6-cyanonaphthalene-2-acetate, 0.91g (3.28mmol) of 1, 1-dimethylethyl [ (7-hydroxy-1, 2, 3, 4-tetrahydronaphthalen-1-yl) -methyl ] carbamate and 1.10g (7.96mmol) of potassium carbonate in 20mL of acetonitrile is heated at reflux for 2 hours. The reaction medium is then evaporated to dryness, eluted with an ethyl acetate/toluene mixture (5: 95 and then 1: 9) and the residue is purified by flash chromatography on silica gel.
1.06g of product was obtained as a white foam.
Melting point: 78-80 ℃.
The yield thereof was found to be 63%.
6.8. Alpha- [ [8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -6-cyanonaphthalene-2-acetic acid ethyl ester hydrochloride
To a solution of 2.17g (4.22mmol) of ethyl 6-cyano- α - [ [8- [ [ [ (1, 1-dimethylethoxy) -carbonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetate in 40mL of dichloromethane was added 8mL of 4N dioxane hydrochloride solution and the mixture was stirred at 20 ℃ for 12 hours. The reaction medium is then evaporated to dryness, the solid is triturated in ether, the ether is removed and dried in vacuo.
1.85g of product are obtained.
Yield: 97 percent.
6.9.6-cyano- α - [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetic acid ethyl ester
To a solution of 0.93g (2.06mmol) of ethyl α - [ [8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -6-cyanonaphthalene-2-acetate hydrochloride in 20mL of dichloromethane were added 0.86mL (6.17mmol) of triethylamine and 0.68g (3.33mmol) of 3-methoxybenzenesulfonyl chloride dissolved in 5mL of dichloromethane, and the mixture was stirred at 20 ℃ for 72 hours. The reaction medium is diluted in 100mL of dichloromethane and then washed with 1M citric acid and then with saturated aqueous sodium chloride. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with methanol/dichloromethane (2: 98).
The product was obtained as an off-white foam.
Yield: 79 percent.
6.10.6- (Aminoiminomethyl) -alpha- [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetic acid ethyl ester hydrochloride
In a solution of 0.967g (1.62mmol) of ethyl 6-cyano- α - [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetate in 10mL of pyridine and 0.5mL of triethylamine, a stream of hydrogen sulfide was bubbled through for 30 minutes. The flask was then capped with a cork stopper and the solution was stirred at ambient temperature for 36 hours. The reaction medium is then evaporated to dryness and the residue is dissolved in 100mL of ethyl acetate. The solution was washed with 1M aqueous citric acid solution and then with saturated aqueous sodium chloride solution. The organic phase is dried over sodium sulfate, filtered and evaporated to dryness. The residue was dissolved in 10mL of acetone, and 0.5mL (8.03mmol) of methyl iodide was added thereto, followed by heating under reflux for 5 hours. The medium is evaporated to dryness and dissolved in 10mL of methanol and heated at reflux in the presence of 0.50g (6.49mmol) of ammonium acetate for 13 hours. The reaction medium is evaporated to dryness and the product is purified by C18 reverse phase flash chromatography, eluting with a mixture of acetonitrile/0.01N hydrochloric acid (1: 1).
0.30g of product is obtained.
Yield: 29 percent.
6.11.6- (Aminoiminomethyl) -alpha- [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-carboxylate
A solution of 0.30g (0.46mmol) of ethyl 6- (aminoiminomethyl) - α - [ [8- [ [ [ [ (3-methoxyphenyl) -methyl ] -sulfonyl ] -amino ] -methyl ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -naphthalene-2-acetate hydrochloride in 10mL of a 2N hydrochloric acid/tetrahydrofuran mixture (1: 2) was heated at reflux for 3 hours. The reaction medium is then evaporated to dryness, eluted with a mixture of acetonitrile/0.01N hydrochloric acid (2: 3) and the product is purified by C18 reverse phase flash chromatography.
Melting point: 180 ℃ is carried out.
Yield: 70 percent.
Example 7(23# Compound)
3- [ [ [ [ [ [ [7- [ (6-aminoiminomethyl) -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] benzoic acid hydrochloride
7.1.3- [ [ [ [ [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] benzoic acid methyl ester
To a solution of 0.38g (1.00mmol) of 6- [ [ [8- (aminomethyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalen-2-carbonitrile hydrochloride and 0.42mL (3.01mmol) of triethylamine in 10mL of dichloromethane cooled to 5 ℃ was added 0.350g (1.41mmol) of 3- [ (chlorosulfonyl) -methyl ] -benzoic acid methyl ester dissolved in 5mL of dichloromethane. The reaction medium is stirred at ambient temperature for 72 hours and then diluted in 100mL of dichloromethane. The solution was washed successively with a 1N aqueous citric acid solution, a saturated aqueous sodium bicarbonate solution and then a saturated aqueous sodium chloride solution. The organic phase is dried over sodium sulfate, filtered and then evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane compound (2: 98).
0.479g of product is obtained in the form of a white foam.
Yield: 86 percent.
7.2.3- [ [ [ [ [7- (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] -benzoic acid
A mixture of 0.47g (0.85mmol) of 3- [ [ [ [ [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] -benzoic acid methyl ester and 0.07g (1.67mmol) of lithium hydroxide monohydrate in 10mL of tetrahydrofuran/water (1: 1) was stirred at ambient temperature for 3 hours. The tetrahydrofuran was distilled off under reduced pressure and the aqueous solution was acidified to pH1 with 1N hydrochloric acid. The product was extracted with ethyl acetate, the organic phase was dried over sodium sulfate, filtered and evaporated to dryness.
A white foamy product was obtained.
Yield: 100 percent.
7.3.3- [ [ [ [ [ [7- [ (6-Aminoiminomethyl) -cyanonaphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] -benzoic acid hydrochloride
A mixture of 0.47g (0.85mmol) of 3- [ [ [ [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] -benzoic acid, 0.15g (2.16mmol) of hydroxylamine hydrochloride and 0.56mL (0.42mmol) of triethylamine in 10mL of anhydrous ethanol was heated to reflux. After 4 hours, the reaction medium is evaporated to dryness. The residue was dissolved in 20mL of a 0.1N isopropanol hydrochloride solution and then evaporated to dryness. This hydrochloride salt was hydrogenated in 20mL of a methanol/acetic acid mixture (9: 1) at 20 ℃ and 40psi pressure in the presence of 0.30g Raney nickel for 14 hours. The reaction medium is filtered and the filtrate is evaporated to dryness. The product is purified by C-18 reverse phase HPLC eluting over 180 minutes with a gradient of 0-100% acetonitrile in 0.001N hydrochloric acid.
0.167g of product was obtained as a white solid.
Melting point: 165 deg.C (decomposition).
Yield: 32 percent.
Example 8: (14# Compound)
6- [ [ [8- [ [ [ imino- [ [ (3-methoxyphenyl) -methyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalen-2-carboximidic acid amide hydrochloride
8.1.1- (isothiocyanato) -3-methoxybenzene
2.3mL (30.17mmol) of thiophosgene is added dropwise to a mixture of 2.74g (20.0mmol) of 3-methoxybenzylamine and 6.0g (60.0mmol) of calcium carbonate in 20mL of water dissolved in 20mL of dichloromethane at ordinary temperature over 60 minutes. The organic phase is separated off after 2 hours, washed with water, dried over sodium sulfate, filtered and evaporated to dryness.
3.29g of oily product are obtained.
Yield: 92 percent.
N- [7- (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -N' - [ (3-methoxyphenyl) -methyl ] -thiourea
To a solution of 0.62g (1.70mmol) of 6- [ (8-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl) -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride and 0.50mL (3.59mmol) of triethylamine in 27mL of toluene were added 0.40g (2.23mmol) of 1- (isothiocyanate) -3-methoxybenzene, and the mixture was heated under reflux for 30 minutes. The reaction medium is allowed to return to ambient temperature and is then washed with a 1N hydrochloric acid solution. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane (2: 98) mixture.
0.654g of product is obtained in the form of a white foam.
Yield: 71 percent.
8.3.6- [ [ [8- [ [ imino- [ [ (3-methoxyphenyl) -methyl ] -amino ] -5, 6, 7, 8-tetrahydronaphthalen-2-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidic acid amide dihydrochloride
A solution of 0.654g (1.29mmol) of N- [7- (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -N' - [ (3-methoxyphenyl) -methyl ] -thiourea in 10mL of pyridine and 1mL of triethylamine is bubbled with a stream of hydrogen sulfide at 20 ℃ for 30 minutes. The reaction mixture was stirred at this temperature for 24 hours with a cork stopper. The reaction medium is then evaporated to dryness and the residue is dissolved in 100mL of ethyl acetate. This solution was washed with a 1M aqueous solution of citric acid and then with a saturated aqueous solution of sodium chloride. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. This sulfamide was dissolved in 50mL of acetone, mixed with 10mL (160.63mmol) of methyl iodide and heated at reflux for 4 hours. The reaction medium was then evaporated to dryness to give 0.871g of a yellow powder. This product was dissolved in 50mL of methanol, 3.0g (38.92mmol) of ammonium acetate was added, and the mixture was heated under reflux for 3 hours. The reaction medium is then evaporated to dryness, eluted with a mixture of acetonitrile/0.01N hydrochloric acid (2: 3) and the product is purified by C18 reverse phase flash chromatography.
0.10g of product is obtained.
Melting point: at 220 ℃.
Yield: 14 percent.
Example 9: (24# Compound)
6- [ [ [8- [ [ [ (phenylmethyl) -sulfonyl ] -amino ] -methyl ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-3-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidamide hydrochloride
9.1.3- (3-bromo-4-methoxybenzene) -propionitrile
2.16g (13.3mmol) of 3- (4-methoxyphenyl) -propionitrile in 13mL of acetic acid are brominated at ambient temperature by adding 0.678mL (13.3mmol) of bromine in the presence of 2.19g (26.6mmol) of anhydrous sodium acetate under the conditions described in tetrahedron 30, page 1053 (1974). After stirring for 2 hours, the reaction medium is poured into 150mL of water and extracted several times with diethyl ether. The organic phase was collected, washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, filtered and evaporated to dryness.
3.085g of oily product were obtained.
Yield: 97 percent.
9.2.4-Methoxybicyclo- [4.2.0] -octa-1, 3, 5-triene-7-carbonitrile
50mg of iron (III) trichloride are added at-78 ℃ to a mixture of 14.5g (63.00mmol) of sodium in liquid ammonia, followed by 8.71g (36.3mmol) of 3- (3-bromo-4-methoxybenzene) -propionitrile, and the medium is stirred at-78 ℃ for 3 hours. The ammonia was distilled off, then sodium chloride was added, and then saturated aqueous ammonium chloride solution was slowly added. The medium is extracted with chloroform and the organic phase is dried over sodium sulfate, filtered and evaporated to dryness. The product was purified by distillation under reduced pressure.
2.69g of oily product are obtained.
Yield: and 47 percent.
9.3.4-Methoxybicyclo [4.2.0] -oct-1, 3, 5-triene-7-methanamine
To a suspension of 0.45g (11.84mmol) of lithium aluminum hydride in 15mL of ether was added 1.50g (9.32mmol) of 4-methoxybicyclo [4.2.0] octa-1, 3, 5-triene-7-carbonitrile dissolved in 5mL of ether. The mixture was stirred at ambient temperature for 1 hour. Hydrolysis was then carried out with 1mL of water, 1mL of 1N sodium carbonate (soude), and then with 5mL of water. The organic phase was decanted and the aqueous phase was extracted again with ether. The organic phase was collected, washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and evaporated to dryness. 1.38g of oily product are obtained.
Yield: 91 percent.
9.4. [ (4-Hydroxybicyclo- [4.2.0] oct-1, 3, 5-trien-7-yl) -methyl ] carbamic acid 1, 1-dimethylethyl ester
To a solution of 1.52g (9.3mmol) of 4-methoxybicyclo [4.2.0] octa-1, 3, 5-trien-7-methanamine in 30mL of dichloromethane cooled to-78 deg.C was added dropwise 37.3mL (37.3mmol) of a 1M solution of boron tribromide in dichloromethane. After addition, the mixture was stirred at-10 ℃ for 1 hour, then cooled again to-78 ℃ and hydrolyzed with 20mL of methanol. The medium was allowed to warm to ambient temperature, then diluted with 50mL of methanol and evaporated to dryness. The residue was co-evaporated three times with benzene. The crude product was dissolved in 50mL of tetrahydrofuran, and 3.89mL (27.91mmol) of triethylamine and 2.0g (9.16mmol) of di-tert-butyl dicarbonate were added. The reaction medium is then stirred at ambient temperature for 14 hours and evaporated to dryness. The residue was dissolved in ethyl acetate, the solution was washed with a chilled 0.1N aqueous hydrochloric acid solution, a saturated aqueous sodium chloride solution, and then the organic phase was dried over magnesium sulfate, filtered and evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with an ethyl acetate/cyclohexane mixture (1: 9).
1.21g of product are obtained.
Yield: 52 percent.
[ [ [ [4- [ (6-cyanonaphthalen-2-yl) -methoxy ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-7-yl ] -methyl ] -carbamic acid 1, 1-dimethylethyl ester
A mixture of 0.518g (2.08mmol) of [ (4-hydroxybicyclo- [4.2.0] -oct-1, 3, 5-trien-7-yl) -methyl ] -carbamic acid 1, 1-dimethylethyl ester, 0.614g (2.50mmol) of 6- (bromomethyl) naphthalene-2-carbonitrile and 0.465g (3.37mmol) of potassium carbonate in 25mL of acetonitrile is heated at 80 ℃ for 3 hours. The reaction mixture was evaporated to dryness and the residue was dissolved in ethyl acetate. The solution was washed with cold 0.1N aqueous hydrochloric acid and then with saturated aqueous sodium chloride. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with an ethyl acetate/cyclohexane mixture (1: 4).
0.412g of product was obtained.
Yield: 48 percent.
9.6.6- [ [ [8- (aminomethyl) -bicyclo- [4.2.0] -oct-1, 3, 5-trien-3-yl ] -oxy ] -methyl ] -naphthalene-2-carbonitrile hydrochloride
To a solution of 0.412g (0.995mmol) [ [ [4- [ (6-cyanonaphthalen-2-yl) -methoxy ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-7-yl ] -methyl ] -carbamic acid-1, 1-dimethylethyl ester in 20mL of dioxane at 0 ℃ was added 1mL of a 4N dioxane hydrochloric acid solution, and the mixture was stirred at 0 ℃ for 10 hours. The liquid was removed from the precipitate, rinsed with dioxane and dried in vacuo.
0.244g of product was obtained.
Melting point: 170 deg.C.
Yield: 70 percent.
N- [ [4- [ (6-cyanonaphthalen-2-yl) -methoxy ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-7-yl ] -methyl ] -phenylmethanesulfonamide
To a solution of 0.244g (0.696mmol) of 6- [ [ [8- (aminomethyl) -bicyclo- [4.2.0] -octa-1, 3, 5-trien-3-yl ] -oxy ] -methyl ] naphthalene-2-carbonitrile hydrochloride and 0.211g (2.09mmol) triethylamine in 6mL of dichloromethane cooled to 5 ℃ was added 0.135g (0.71mmol) of a-toluenesulfonyl chloride. The solution was then stirred at 20 ℃ for 15 hours. The reaction medium is then evaporated to dryness and the residue is taken up in 100mL of ethyl acetate. This solution was washed with a 1N aqueous hydrochloric acid solution and then with a saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness. The product was purified by flash chromatography on silica gel eluting with a mixture of ethyl acetate/n-hexane (3: 7) and then 100% ethyl acetate.
0.20g of product is obtained.
Yield: 61 percent.
9.8.6- [ [ [8- [ [ [ (phenylmethyl) -sulfonyl ] -amino ] -methyl ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-3-yl ] -oxy ] -methyl ] -naphthalene-2-carboximidamide hydrochloride
A solution of 0.20g (0.42mmol) of N- [ [4- [ (6-cyanonaphthalen-2-yl) -methoxy ] -bicyclo- [4.2.0] -oct-1, 3, 5-trien-7-yl ] -methyl ] -phenylmethanesulfonamide in 8mL of a triethylamine/pyridine mixture (1: 9) was bubbled with hydrogen sulfide gas for 5 minutes at ambient temperature. At this point the container was stoppered and the solution was stirred at 20 ℃ for 48 hours. The reaction mixture was evaporated to dryness, the residue was dissolved in 5mL of acetone and heated at reflux in the presence of 0.656g (4.62mmol) of methyl iodide for 1 hour. The evaporation to dryness, the crude thioamide was dissolved in 5mL of methanol and heated at reflux in the presence of 0.065g (0.84mmol) of anhydrous ammonium acetate for 2 hours. The reaction medium is evaporated to dryness and the residue is dissolved in 10mL of 0.1N isopropanol hydrochloride solution and then evaporated to dryness. The product was purified by C-18 reverse phase HPLC over 180 minutes eluting with a gradient of 0-100% acetonitrile in 0.001N hydrochloric acid.
0.86g of product is obtained as a white solid.
Melting point: 125 ℃.
Yield: 39 percent.
Example 10: (57# Compound)
3- [ [ [ [ [ [ [7- [ [6- [ [ (ethoxycarbonyl) -amino ] -aminoiminomethyl ] -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -amino ] -carbonyl ] -amino ] -methyl ] -benzoic acid methyl ester
To a suspension of 0.18g (0.335mmol) of methyl 3- [ [ [ [ [ [7- [ [6- (aminoiminomethyl) -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -amino ] -carbonyl ] -amino ] -methyl ] benzoate in 15mL of tetrahydrofuran cooled to 0 ℃ was added 0.064mL (0.37mmol) of N, N-diisopropylethylamine followed by 0.034mL (0.35mmol) of ethyl chloroformate. The mixture was stirred at ambient temperature for 1 hour and the reaction mixture was diluted in 50mL of ethyl acetate. The solution was then washed with 0.1N aqueous hydrochloric acid, then with saturated aqueous sodium bicarbonate and finally with saturated aqueous sodium chloride. The organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The crude product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (5: 95).
0.130g of product is obtained as a white solid.
Melting point: 118 deg.C (decomposition).
Yield: and 64 percent.
Example 11: (84# Compound)
3- [ [ [ [ [ [ [7- [ [6- [ amino- (hydroxyimino) -methyl ] -naphthalen-2-yl ] -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] benzoic acid methyl ester hydrochloride
A solution of 0.50g (0.90mmol) of methyl 3- [ [ [ [ [7- [ (6-cyanonaphthalen-2-yl) -methoxy ] -1, 2, 3, 4-tetrahydronaphthalen-1-yl ] -methyl ] -amino ] -sulfonyl ] -methyl ] -benzoate (see example 7.1.), 0.154g (2.22mmol) of hydroxylamine hydrochloride and 0.31mL (2.22mmol) of triethylamine in 10mL of methanol was heated at reflux overnight. The reaction medium is evaporated to dryness and the residue is triturated in water. The solid was dewatered, rinsed with water and dried under vacuum at 40 ℃. The crude product was purified by flash chromatography on silica gel eluting with a methanol/dichloromethane mixture (5: 95) and then converted to the hydrochloride salt by means of 2N ethyl chloride solution.
0.23g of product is obtained as a white solid.
Melting point: 155 ℃.
Yield: 41 percent.
Watch (A) All compounds are present as the hydrochloride salt except the indicated compound which is the dihydrochloride salt. In the table: - "dec" means that the compound decomposes at its melting point, - "tBu" means tert-butyl, i.e.1, 1-dimethylethyl, - "nBu" means straight-chain butyl, - "Et" means ethyl
The compounds of the invention, as subjects of pharmaceutical research, have proven their significance as substances with therapeutic activity.
The compounds of the invention were tested in particular for VII/VIIa coagulation factor inhibition.
Principle of Ki factor VIIa test
The purpose of this test was to measure the amidolytic activity of the factor VIIa/tissue factor complex on chromogenic substrates in the presence of various concentrations of the inhibitor to be tested. If a compound increases the Km value of factor VIIa for the substrate of the inhibitor, that is to say decreases the affinity of factor VIIa for its substrate, then this compound is a so-called competitive inhibitor for the inhibitor.
This amidolytic activity of factor VIIa tested at one concentration was measured kinetically (calculation speed), and the time-dependent cleavage of the substrate (both measured concentrations) was determined by means of a microspot counter which measures the release of p-nitroaniline at 405 nm. This compound was tested at 7 concentrations.
Ki was determined according to the Dixon method, in which the reciprocal velocity is plotted as a function of the compound concentration at each substrate (S1 and S2) concentration.
The intersection of the linear regression lines projected on the X-axis determines the inhibitor concentration corresponding to Ki.
Biological agent
The factor VIIa used is a recombinant human (produced in CHO cells)
Tissue factor is a human recombinant (produced in E.coli (E.coli)) corresponding to the extracellular soluble fraction (amino acids 1-219). The FVIIa factor/tissue factor complex was pre-formed by culturing factor VIIa and tissue factor in the presence of 5mM calcium chloride at a molar concentration ratio of 1/5, and the final concentration for FVIIa factor in the presence of 18.75nM tissue Factor (FT) was 3.75 nM.
Buffer TBSA: tromethamine (Tris)50mM, pH 7.5, sodium chloride 100mM, BSA 0.1%.
FVIIa factor/FT complex used in TBSA buffer +5mM calcium chloride is 3.75nM/18.75 nM.
The chromogenic substrate CBS-3447(HD-CHG-But-Arg-pNA) was used in concentrations of 0.66 and 2.64 mM.
The compound tested is a 1mM solution. The outline of the experiment was followed by the sequential administration of reagents (no culture; final concentration)
Compound (I) | Substrate | FVIIa/FT Complex |
7 concentrations (+ control group) | S1=0.66mMS2=2.64mM | 3.5nM/18.5nM |
25μl | 50μl | 25 μ l (volume of each well) |
The compounds of the invention preferably have Ki's of less than 1 μ M.
Another study of the compounds of the invention has been directed to anticoagulant activity.
Anticoagulant activity was measured on an arterial-venous shunt model.
Principle of testing
Tissue factor-dependent thrombosis in rats or guinea pigs was achieved by placing an arterio-venous shunt into which a section of cotton yarn impregnated with thromboplastin (tissue factor: TF) was inserted.
Operating procedure
Rats (Sprague Dawley) or guinea pigs (Hartley) with an average body weight of 300-350 g were anesthetized with sodium pentobarbital (60mg/kg ip). The femoral vein (rat) or right jugular vein (guinea pig) was cannulated for intravenous injection, and the left and right jugular veins were cannulated with 0.9% saline to make up the shunt. After 5 minutes of intravenous administration of the compounds (treatment group) or their solvents (control group), two cannulae were connected by a flexible plastic tube having an inner diameter of 3mm and a length of 6cm and containing cotton yarn impregnated with thromboplastin to form a shunt. Blood circulation was re-established for 5 minutes (rats) or 10 minutes (guinea pigs). At this point the shunt was removed and the cotton yarn associated with the thrombus was removed and weighed immediately.
Results show
The mean values (. + -. ESM) of thrombus weights were tested for different groups. The percentage of thrombus weight reduction for each treatment group relative to the control group was calculated as DA50This is the dose of compound used to inhibit 50% of the thrombus weight in control animals.
DA of the Compound of the present invention50Preferably less than 10 mg/kg.
The results of this physiological experiment show that the compounds of the invention have the property of inhibiting factor VII/VIIa.
Thus, they can be used to treat and prevent different forms of diseases involving factor VII/VIIa and the coagulation chain. They can therefore be used for the treatment of thrombosis of veins, arteries or coronary arteries, disseminated intravenous thrombosis, restenosis following angioplasty, prevention of reocclusion which is aggravated after thrombosis, arterial fibrillation, pulmonary embolism, edema, septic shock, tumor-induced hypercoagulability, treatment of bradycardia, inflammation, pulmonary fibrosis or prevention of unstable angina.
For this purpose, the compounds can be in various forms suitable for oral, parenteral, intravenous administration, such as tablets, pills, dragees, capsules, suspensions, drinkable solutions or injectable solutions, together with suitable excipients, in doses ranging from 0.1mg to 1g per day, to be taken in single or several portions.
It may also be in various forms suitable for transdermal and ocular (occulaire) administration.
Claims (5)
1. A compound of formula (I) in racemic form or in the form of a pure enantiomer, or in the form of a mixture of enantiomers, or in the form of the free acid or free base, or in the form of a pharmaceutically acceptable addition salt:wherein: r1Represents a hydrogen atom, and is represented by,
or an amino group, or a salt thereof,
or C1~C4An alkyl group, a carboxyl group,
or C1~C6An alkoxycarbonyl group, a carbonyl group,
or an-OH group, or a group,the radicals may be in the form of tautomersIn the form of radicals R2To represent
C1~C6An alkyl group which may be substituted with 1 to 3 fluorine atoms,
or a cyclohexyl-methyl group,
or 2, 3-dihydro-1, 4-benzodioxo-7-ylmethyl,
or benzo-1, 3-dioxolan-6-ylmethyl,
or phenyl, benzyl or phenethyl, wherein the phenyl groups can be respectively and independently selected from 1 to 3-N (CH)3)2Trifluoromethoxy group, methylthio group, C1~C4Alkoxy, trifluoromethyl, amino, nitro, C1~C4Alkyl, trifluoromethoxy, halogen, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Wherein R is8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-CH2The group Q, where Q is a heterocyclic group, may be selected from the group consisting of-N (CH)3)2Trifluoromethoxy group, C1~C4Alkoxy, trifluoromethyl, amino, nitro, C1~C4Alkyl, trifluoromethoxy, halogen, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Is substituted by radicals, where R8Represents a hydrogen atom or C1~C4Alkyl radical, R3And R5Independently of each other represent
A hydrogen atom or a fluorine atom, or a salt thereof,
or C1~C4An alkyl group, a carboxyl group,
or-COOH, or a group of-COOH,
or a hydroxyl group, or a mixture of hydroxyl groups,
or-N (CH)3)2,
or-Y-CH2CO2H, where Y represents an oxygen atom or a nitrogen atom, R4To represent
A hydrogen atom, and a nitrogen atom,
or C1~C4An alkyl group, a carboxyl group,
or- (CH)2)p-COOR8Where p is equal to 0, 1 or 2, R8Represents a hydrogen atom or C1~C4Alkyl, X represents
-(CH2)mA group, where m is equal to 0, 1 or 2,
or-CR6R7-CH2-or-CH2-CR6R7A group, where R6And R7Each independently represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-NH-CO-or-CO-NH-groups,
or-NH-CH2-、-CH2-NH-、N(CH2)-CH2-、-CH2-N(CH3)-、-N(CH2CH3)-CH2-or-CH2-N(CH2CH3) A group, orA group, wherein W represents an oxygen atom or an NH group, and Z represents
-a CH-group, in which,
or a nitrogen atom, and-A-B-C-represents
-a NH-CO-NH-group,
or an-NH-C (NH) -NH-group,
or- (CH)2)n-CO-NH groups, where n is equal to 0 or 1,
or- (CH)2)q-NR8-SO2-a group, where q is equal to 0, 1 or 2, and R8As before, represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or- (CH)2)q-NH-CO-group, where q is equal to 0 or 1,
or-CH2-NH-CO-NH-groups.
2. The device of claim 1A compound in racemic form or in the form of a pure enantiomer, or in the form of a mixture of enantiomers, or in the form of a free acid or a free base, or in the form of a pharmaceutically acceptable addition salt, characterized in that R is1To represent
A hydrogen atom, and a nitrogen atom,
or C1~C4An alkoxycarbonyl group, a carbonyl group,
or-OH, R2To represent
C1~C6Alkyl, which may be substituted with trifluoromethyl,
or a cyclohexyl-methyl group,
or 2, 3-dihydro-1, 4-benzodioxo-7-ylmethyl,
or benzo-1, 3-dioxolan-6-ylmethyl,
or phenyl, benzyl or phenethyl, each of which may be substituted by 1 to 3 substituents independently selected from the group consisting of-N (CH)3)2Trifluoromethoxy group, methylthio group, C1~C4Alkoxy, trifluoromethyl, amino, nitro, C1~C4Alkyl, trifluoromethoxy, halogen, -SO2CH3Hydroxy or-COOR8or-OCH2CO2R8Wherein R is8Represents a hydrogen atom or C1~C4An alkyl group, a carboxyl group,
or a group-CH2Q, where Q is a heterocyclic group, which may be selected from C1~C4Alkoxy, amino or-COOR8Wherein R is8Represents a hydrogen atom or C1~C4Alkyl radical, R3And R5Independently of each other represent
A hydrogen atom, and a nitrogen atom,
or-COOH, or a group of-COOH,
or-CH3,R4To represent
A hydrogen atom, and a nitrogen atom,
or-COOH, X represents
-(CH2)mA group, where m is equal to 0 or 2,
or-CR6R7-CH2A group, where R6And R7Each independently representHydrogen atom or C1~C4An alkyl group, a carboxyl group,
or-NH-CO-or-NH-CH2-a group of,
or-NH-CH2-or-CH2-N(CH2CH3) The radical Z represents a-CH-group and-A-B-C-represents
-a NH-CO-NH-group,
or- (CH)2)n-a CO-NH-group, where n is equal to 0 or 1,
or- (CH)2)q-NR8-SO2-a group, where q is equal to 0, 1 or 2, and R8Represents a hydrogen atom, and is represented by,
or- (CH)2)q-NH-CO-group, where q is equal to 0 or 1,
or-CH2-a NH-CO-NH-group,
or-CH2-CO-NH-groups.
3. A process for the preparation of a compound of formula (I) according to claim 1 or 2, characterized in that a compound of formula (II) is reacted with a compound of formula (III) in the presence of a base to give a compound of formula (IV),wherein R is3And R4D represents a leaving group as defined in claim 1 or 2,wherein R is5X, Z, A and B are as defined in claim 1 or 2, and GP represents a protecting group for an amine or a carboxylic acid,deprotecting it to give a compound of formula (V)And optionally reacting it with different reagents as follows to give compounds of general formula (VI):
in the formula (V), A represents- (CH)2)q-a group, where q may be 0,1 or 2, BH represents-NHR8,R8When defined as in claim 1, compounds of the formula (V) are reacted with compounds of the formula R2-SO2Sulfonyl chloride reaction of Cl, R2As defined in claim 1, to give a compound of the general formula (VI) in which A represents- (CH)2)q-a group, where q may be equal to 0, 1 or 2, B represents-NR8-, and C represents-SO2-a group;
in the formula (V), A represents- (CH)2)qA group, where q may be equal to 0 or 1, BH represents an amine function, a compound of formula (V) with a compound of formula R2-N ═ C ═ O isocyanate, or with triphosgene and then with the general formula R2-NH2Reaction of amines, R2Is defined in claim 1, to give a compound of the general formula (VI) in which A represents-NH-or-CH2-NH-group, B represents-CO-group and C represents-NH-group;
in the formula (V), A represents- (CH)2)q-a group, where q may be 0 or 1, BH represents an amine function, in the presence of an organic base, a compound of formula (V) with a compound of formula R2-COCl acid chloride reaction, in which formula R2Two cases as defined in claim 1; or a compound of the formula (V) with a compound of the formula R in the presence of a coupling agent2-CO2H carboxylic acid reaction of formula (I) wherein R2Two cases as defined in claim 1; to obtain a compound of the general formula (VI) wherein A represents- (CH)2)q-, where q may be equal to 0 or 1, B represents an-NH-group and C represents a-CO-group;
in the formula (V), A represents- (CH)2)n-a group, where n may be equal to 0 or 1, BH representing-CO2H, a compound of the formula (V) and a compound of the formula R2-NH2Reaction of amines, where R2As defined in claim 1, to give a compound of the general formula (VI) in which A represents- (CH)2)n-a group, where n may be equal to 0 or 1, B represents a-CO-group and C represents a-NH-group;
in formula (V), A represents- (CH)2)q-a group, where q is equal to 0 or 1 and BH represents an amine function, orA compound of formula (V) and formula R2Reaction of N ═ C ═ S isothiocyanate, where R is2As defined in claim 1, to obtain a thiourea, and converting the thiourea thus obtained into a guanidine by alkylation with methyl iodide followed by substitution thereof with an ammonia source, to obtain a compound of the general formula (VI) wherein a-B-C represents an-NH-C (NH) -NH-group;
compounds of formula (VI) wherein R is formed by rearrangement of the nitrile function to the hydroxyamidine function1A compound of formula (I) which is a hydroxyl group, which is then reduced to an amidine to give a compound of formula (I), which is optionally reacted with an alkyl chloroformate in the presence of a base to give R in the formula1Is C1~C6Alkoxycarbonyl compounds of the general formula (I).
4. A medicament, characterized in that it comprises a compound according to claim 1 or 2.
5. A pharmaceutical composition comprising a compound according to claim 1 or 2 together with any pharmaceutically acceptable excipient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/05632 | 1999-05-04 | ||
FR9905632A FR2793247B1 (en) | 1999-05-04 | 1999-05-04 | DERIVATIVES OF 6 - [[(ARYL AND HETEROARYL) OXY] METHYL] NAPHTALENE-2- CARBOXIMIDAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1359373A true CN1359373A (en) | 2002-07-17 |
Family
ID=9545179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00809874A Pending CN1359373A (en) | 1999-05-04 | 2000-04-25 | 6[(aryl and heteroaryl)oxy] methyl] naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1177169A1 (en) |
JP (1) | JP2002543176A (en) |
KR (1) | KR20020010634A (en) |
CN (1) | CN1359373A (en) |
AU (1) | AU4303700A (en) |
BG (1) | BG106048A (en) |
BR (1) | BR0010230A (en) |
CA (1) | CA2371284A1 (en) |
CZ (1) | CZ20013959A3 (en) |
EE (1) | EE200100579A (en) |
FR (1) | FR2793247B1 (en) |
HK (1) | HK1042288A1 (en) |
HU (1) | HUP0200893A3 (en) |
IL (1) | IL146107A0 (en) |
IS (1) | IS6121A (en) |
MX (1) | MXPA01011180A (en) |
NO (1) | NO20015387L (en) |
PL (1) | PL356122A1 (en) |
SK (1) | SK15932001A3 (en) |
TR (1) | TR200103215T2 (en) |
WO (1) | WO2000066545A1 (en) |
YU (1) | YU78001A (en) |
ZA (1) | ZA200108758B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109438272A (en) * | 2018-11-16 | 2019-03-08 | 常州大学 | The synthetic method of C5a receptor antagonist W-54011 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4209659B2 (en) | 2001-11-15 | 2009-01-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Amidino derivative and anticoagulant and thrombosis therapeutic agent using the same |
US7217794B2 (en) | 2003-04-02 | 2007-05-15 | Daiamed, Inc. | Compounds and methods for treatment of thrombosis |
JP5016592B2 (en) | 2006-03-24 | 2012-09-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Triazolone derivatives |
JPWO2009038157A1 (en) * | 2007-09-21 | 2011-01-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2,3-dihydro-iminoisoindole derivatives |
TW201206905A (en) | 2010-05-20 | 2012-02-16 | Eisai R & Amp D Man Co Ltd | Prodrug of triazolone compound |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
JP3388803B2 (en) * | 1993-05-20 | 2003-03-24 | 第一製薬株式会社 | Method for producing optically active 7-amidinonaphthalene derivative |
ATE233240T1 (en) * | 1994-12-02 | 2003-03-15 | Yamanouchi Pharma Co Ltd | NEW AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF |
-
1999
- 1999-05-04 FR FR9905632A patent/FR2793247B1/en not_active Expired - Fee Related
-
2000
- 2000-04-25 BR BR0010230-0A patent/BR0010230A/en not_active Application Discontinuation
- 2000-04-25 CA CA002371284A patent/CA2371284A1/en not_active Abandoned
- 2000-04-25 AU AU43037/00A patent/AU4303700A/en not_active Abandoned
- 2000-04-25 YU YU78001A patent/YU78001A/en unknown
- 2000-04-25 IL IL14610700A patent/IL146107A0/en unknown
- 2000-04-25 TR TR2001/03215T patent/TR200103215T2/en unknown
- 2000-04-25 JP JP2000615376A patent/JP2002543176A/en not_active Withdrawn
- 2000-04-25 CN CN00809874A patent/CN1359373A/en active Pending
- 2000-04-25 HU HU0200893A patent/HUP0200893A3/en unknown
- 2000-04-25 MX MXPA01011180A patent/MXPA01011180A/en unknown
- 2000-04-25 KR KR1020017014068A patent/KR20020010634A/en not_active Application Discontinuation
- 2000-04-25 CZ CZ20013959A patent/CZ20013959A3/en unknown
- 2000-04-25 PL PL00356122A patent/PL356122A1/en not_active Application Discontinuation
- 2000-04-25 EE EEP200100579A patent/EE200100579A/en unknown
- 2000-04-25 WO PCT/FR2000/001087 patent/WO2000066545A1/en not_active Application Discontinuation
- 2000-04-25 EP EP00922738A patent/EP1177169A1/en not_active Withdrawn
- 2000-04-25 SK SK1593-2001A patent/SK15932001A3/en unknown
-
2001
- 2001-10-23 IS IS6121A patent/IS6121A/en unknown
- 2001-10-24 ZA ZA200108758A patent/ZA200108758B/en unknown
- 2001-10-24 BG BG106048A patent/BG106048A/en unknown
- 2001-11-02 NO NO20015387A patent/NO20015387L/en not_active Application Discontinuation
-
2002
- 2002-05-14 HK HK02103641.5A patent/HK1042288A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109438272A (en) * | 2018-11-16 | 2019-03-08 | 常州大学 | The synthetic method of C5a receptor antagonist W-54011 |
Also Published As
Publication number | Publication date |
---|---|
ZA200108758B (en) | 2002-10-24 |
EP1177169A1 (en) | 2002-02-06 |
YU78001A (en) | 2004-07-15 |
BG106048A (en) | 2002-05-31 |
NO20015387D0 (en) | 2001-11-02 |
JP2002543176A (en) | 2002-12-17 |
PL356122A1 (en) | 2004-06-14 |
HUP0200893A2 (en) | 2002-07-29 |
NO20015387L (en) | 2002-01-07 |
KR20020010634A (en) | 2002-02-04 |
TR200103215T2 (en) | 2002-07-22 |
CA2371284A1 (en) | 2000-11-09 |
CZ20013959A3 (en) | 2002-02-13 |
AU4303700A (en) | 2000-11-17 |
FR2793247B1 (en) | 2001-06-22 |
HUP0200893A3 (en) | 2002-11-28 |
WO2000066545A1 (en) | 2000-11-09 |
IS6121A (en) | 2001-10-23 |
HK1042288A1 (en) | 2002-08-09 |
BR0010230A (en) | 2002-02-13 |
FR2793247A1 (en) | 2000-11-10 |
SK15932001A3 (en) | 2002-04-04 |
IL146107A0 (en) | 2002-07-25 |
EE200100579A (en) | 2003-02-17 |
MXPA01011180A (en) | 2002-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1066729C (en) | Benzimidazole derivatives, their preparation and their therapeutic use | |
CN1030251C (en) | Substituted 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives | |
CN1034497C (en) | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | |
CN1198613C (en) | Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical composition containing the same | |
CN1213658C (en) | Picolinamide derivatives and pest controllers containing same as active ingredient | |
CN1064682C (en) | Pyrrolidine derivatives having phospholipase A2 inhibitor activity | |
CN1247544C (en) | Anthranilic acid amides with heteroarylsulfonyl side chain, method for production thereof, use thereof as medicament or diagnostic agent and phamaceutical preparations containing same | |
CN1812980A (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
CN1016778B (en) | Spiro-substituted glutaramida diuretic agents | |
CN1518541A (en) | Phenyl derivatives | |
CN1134148A (en) | Antithrombotic amidinophenylalanine and amidinopyridylalanine derivs | |
CN1545509A (en) | Piperidine derivatives useful as modulators of chemokine receptor activity | |
CN1688557A (en) | Thiazole compounds for treatment of neurodegenerative disorders | |
CN1462268A (en) | Substituted cinnamic acid guanidides, method for the production thereof, their use as medicament, and medicine containing these compounds | |
CN1221524C (en) | Diphenyl ether compounds for therapeutic use | |
CN1028757C (en) | Process for preparing heterocyclic derivatives | |
CN1268117A (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
CN1138037A (en) | Adhesion receptor antagonists | |
CN1111630A (en) | Adhesion receptor antagonists | |
CN87105501A (en) | New phenoxyacetic acid derivative and preparation method thereof and contain its and form as the medicine of activeconstituents | |
CN1458922A (en) | Urea derivative and adhesive-molecule inhibitor containing same as ctive ingredient | |
CN1359373A (en) | 6[(aryl and heteroaryl)oxy] methyl] naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof | |
CN1514823A (en) | Oxalic acid derivatives | |
CN1283622C (en) | Cyclohexyl (alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | |
CN1208329C (en) | Aniline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |